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Hearing loss is the most common sensory disorder worldwide and > 50% of cases 
can be attributed to single gene mutations. I used a targeted candidate gene approach and 
Sanger sequencing to screen genomic DNA from 101 deaf probands with Newfoundland 
ancestry for pathogenic mutations in deafness genes. First I screened for mutations in 
WFS1, TMPRSS3, and PCDH15 that were previously identified in this population, then 
for mutations in Cx26 and Cx30, and mutations in the mitochondrial genes MTRNR1 and 
MTTS1. Finally, genes were targeted based on patterns of hearing loss as seen on patient 
audiograms. Although several probands were “solved” by this approach, none had 
mutations in WFS1, TMPRSS3 or PCDH15. One proband had digenic mutations in Cx26 
and Cx30 and two probands inherited the A1555G mutation in MTRNR1. In order to 
decipher several variants of unknown pathogenicity and solve more families, further 
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1.Introduction 
1.1 Purpose of Study 
	  
The objective of this project was to determine the underlying genetic cause of 
deafness in probands (affected individuals) from Newfoundland and Labrador. These 
individuals had been diagnosed with hearing loss. An attempt to identify genetic causes 
was carried out using modern molecular genetic techniques.     
1.2 Overview of Hearing Loss 
 
Hearing loss is one of the most common sensory disorders worldwide, affecting 
1-3 in 1000 children at birth or in early childhood, and is caused by many known 
environmental and genetic factors (Retrieved from www.cdc.gov/ncbddd/hearingloss/ 
ehdi-data2009.html on April 24, 2014). The prevalence of pre-lingual hearing loss 
increases if young children are included and all degrees of hearing loss are considered. 
Even hearing loss that follows environmental affliction (for example infection, acoustic 
trauma, or exposure to ototoxic drugs) is likely influenced by a genetic susceptibility (Ito 
et al., 2010; Petersen et al., 2006,;Nance, 2003; Keats & Berlin, 2002). The number of 
individuals affected by hearing loss increases as the population ages, with hearing 
impairment affecting 25% of individuals between the age of 50 and 65, and 50% of 
individuals over the age of 85 (Liu et al., 2007).  Like early onset hearing loss, late onset 
hearing loss can also be attributed to a variety of causes including environmental factors, 
medical disorders and their treatment, and genetic susceptibility (Liu et al., 2007).  
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 Hearing loss can be classified into three different types based on clinical 
presentation: conductive, sensorineural, and mixed – a combination of conductive and 
sensorineural. Conductive hearing loss results from abnormalities of the anatomic 
components of the ear that transfer sound waves to the cochlea, such as the external ear, 
the ear canal, ossicles (malleus, incus, stapes), tympanic membrane, oval window, round 
window, or middle ear space (Fig.1.1). Sensorineural hearing loss results from the 
dysfunction of the auditory pathway components that convert sound wave vibrations into 
an electrical impulse that is transferred to the auditory cortex in the brain. Therefore this 
type of hearing loss is caused by abnormalities within the cochlea, and/or auditory 
(cochlear) nerve, or in rare cases auditory brainstem, or auditory structures in the brain 
(Griffith, 2002) (Fig.1.1). 
More than fifty percent of hearing loss cases can be attributed to an underlying 
genetic cause (Ito et al., 2010; Norton 1991), and can be further categorized into two 
distinct groups: syndromic (SHL) or nonsyndromic (NSHL). When an individual presents 
with hearing loss along with other abnormalities, it is known as SHL. This occurs in 
approximately 30% of diagnosed individuals with over 400 hearing loss syndromes 
having been described, including Usher syndrome (hearing loss along with retinitis 
pigmentosa – loss of peripheral vision and night blindness), Pendred syndrome (hearing 
loss along with thyroid problems), and Jervell and Lange-Nielson syndrome (hearing loss 
along with cardiac dysrhythmia) (Van Camp et al., 1997; Hilgert et al., 2009). When 
hearing loss is not associated with any other abnormalities it is known as NSHL; 70% of 
hearing loss cases fall into this category (Hilgert et al., 2009; Van Camp et al., 1997).       
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NSHL can follow every known pattern of Mendelian inheritance including 
autosomal recessive (AR), autosomal dominant (AD), and X-linked. There are also 
mutations in the mitochondrial genome that result in non-Mendelian maternal 
inheritance, and NSHL. A set of nomenclature rules has been assigned to the different 
types of genetic deafness to classify them as AD, AR or X-linked (mitochondrial hearing 
loss does not have a specific nomenclature) and these types are named under the acronym 
DFN (from the word “deafness”). Following DFN are the letters ‘A’ or ‘B’, ‘A’ meaning 
AD inheritance (DFNA) or ‘B’ meaning AR inheritance (DFNB). When DFN is present 
without an A or B, it refers to X-linked deafness (Piatto et al., 2009). AR inheritance 
means the individual has to inherit two copies of a mutated gene in order to be affected, 
this type of inheritance accounts for 77-88% of genetic NSHL. With AD inheritance, 
which accounts for 10-20% of inherited NSHL, the individual will be affected if only one 
copy of a mutated gene is inherited. The mutated gene can come from either parent, if 
one parent is affected each offspring has a 50% chance of inheriting the mutated gene, if 
both parents are affected the chance of inheritance increases to 75%.  X-linked disorders 
are passed on from parent to offspring on the X chromosome and can be dominant or 
recessive, the most characteristic feature of these disorders is the absence of male-to-male 
transmission. X-linked disorders also severely affect males but have variable expression 
in females due to X chromosome inactivation, which occurs in early embryogenesis in 
female germ line cells to compensate for the X-linked gene dosage difference between 
males and females. X-linked inheritance accounts for 1-2% of NSHL. Finally, 
mitochondrial hearing loss is caused by a mutation in the genome of mitochondria, an 
	  
	  
	   4 
organelle found within all human cells, more frequently in cells that require an abundance 
of adenosine triphosphate (ATP), such as muscle cells, due to the fact that mitochondria 
generate most of the cell’s supply of this form of chemical energy. Mitochondrial genetic 
disorders can only be passed down from a mother to her offspring because the 
mitochondria in an embryo come from the ovum. None of the mitochondria contained in 
the sperm are passed on to the offspring; therefore you will only see female-to-male and 
female-to-female transmission in mitochondrial genetics. Mitochondrial hearing loss is 
more variable and harder to detect than other types of NSHL, and accounts for 1-20% of 
NSHL depending on the population.	  (Nance, 2003, Petersen, 2012, Sirmaci, 2012) 
(Fig.1.2). When evaluating the frequency of NSHL and SHL within the different types of 
Mendelian inheritance, it can be shown that the most common type of hereditary hearing 
loss is nonsyndromic autosomal recessive.  
In order to categorize hearing loss into specific modes of inheritance prior to 
genetic testing, two methods can be used, first a pedigree with a family history of a 
defined hearing loss diagnosis is required so the hearing loss can be traced throughout the 
family. Secondly, an audioprofile can be created using the person’s behavioural 
audiogram and other pertinent information including age of onset and number of affected 
relatives. Use of these classification methods helps to narrow down the number of genes 
that are screened during the genetic testing phase, making the process more efficient.  
For the first method, a pedigree is created using information from the affected 
individual and family members as well as medical and census records. The pedigree will 
show the relationships between individuals and their affection status. Even with a clear 
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family history, classification can be difficult, as some types of hearing loss have reduced 
penetrance. Penetrance is directly linked to variable expressivity, as both influence the 
effect that genetic mutations have on the population. Penetrance indicates the number of 
people who have a genetic mutation and display the disorder. Expressivity refers to the 
symptoms displayed by an individual that has a genetic disorder. More specifically 
variable expressivity is the phenomenon where different people have the same genetic 
mutation but display different symptoms or different severities of the same symptom.  
For example, hearing loss can have variable expressivity, meaning a number of 
individuals within a family have hearing loss but at different severities, some with a 
subclinical phenotype (i.e. a mild form of hearing loss that is undetectable by standard 
behavioural audiogram). In a study, ten individuals from a family are found to have a 
mutation in a deafness gene, though only six of these family members display hearing 
loss; this would be reduced penetrance, and it is common in AD disorders. It may make it 
difficult for a researcher to confirm that the mutation is the cause of the disorder. Given 
the fact that everyone has a different genetic background, a mutation can have a lowered 
penetrance, so low that it may not cause a detectable phenotype. Therefore an individual 
could have a mutation that causes hearing loss, but may not display it (i.e. variable 
expressivity). These types of cases make it difficult to consistently identify the mode of 
inheritance, especially in families with few affected individuals. Knowing the mode of 
inheritance is important because it helps to narrow down the list of candidate genes, as 
mutations in some genes are more likely to cause a specific type of hearing loss. AD 
disorders will often show up in every generation of a pedigree (called a vertical 
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inheritance pattern) and are transmitted from mothers or fathers to both sons and 
daughters. AR disorders show a horizontal pattern where they are generally seen in only 
one sibship, and usually the affected siblings will have unaffected parents. Like 
autosomal dominant inheritance, the number of affected females and males is nearly 
equal; meaning the chance of inheriting a mutation is not affected by sex. X-linked 
dominant disorders have a specific pattern where the disorder is passed to all daughters 
from an affected male and affected females will pass the disease to half of their sons and 
daughters. The crisscross pattern is often described as a “Knight’s Move inheritance” 
after the move used in the game of chess. X-linked recessive disorders will appear in 
more males than females (due to the fact that males only have one X chromosome), and 
an affected male will not pass the disorder on to any of his offspring (although the 
females may be carriers) (Griffiths et al., 1999). Mitochondrial disorders display a pattern 
of matrilineal (maternal) inheritance because the mitochondrial genome is inherited from 
the mother and not the father; therefore only children of affected females will potentially 
manifest the disorder, whereas offspring of an affected male will not be affected 
(Strachan et al., 1999). Understanding the inheritance pattern can help when counseling 
families regarding prevention of the disorder.  
The second method used to categorize hearing loss into specific modes of 
inheritance is audioprofiling, where several audiograms at different ages are plotted on 
the same graph. The different ages can be from a single individual or from different 
members of the same family (Smith et al., 2013). A helpful online tool, called 
AudioGene (audiogene.eng.uiowa.edu )(Hildebrand et al., 2008), was developed to aid in 
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audioprofiling, it “analyzes audiometric data and predicts the likely underlying genetic 
cause of hearing loss based on known phenotypic parameters” (Hildebrand et al., 2008). 
The user inputs the proband’s audiogram and age, and the same information for all 
affected relatives, then the tool will identify a list of candidate genes/loci based on this 
information. An audiogram is a graphic display of the softest sounds an individual can 
hear at each specific frequency. The frequency, the pitch of a sound, is measured in Hertz 
(Hz), and the intensity, the loudness of a sound, is measured in decibels (dB). The 
audiogram (Fig.1.3) is produced following a hearing test by an audiologist. The pattern of 
an audiogram can give an indication as to what type of hearing loss affects the individual 
(Retrieved from http://www.raisingdeaf kids.org/hearingloss/testing/ audiogram/ on 
August 23, 2013). On the audiogram, a reverse slope indicates low-frequency hearing 
loss, mid-frequency loss is shown as a dip in the middle of the graph, also known as a 
“cookie-bite”. Loss of high and low frequencies is known as a “reverse cookie-bite loss” 
as the individual can hear better in the mid-frequency range creating a peak in the middle 
of the graph. High frequency hearing loss is also known as sloping loss due to the sloped 
configuration, and flat loss involves a similar hearing loss at all frequencies (Fig. 1.4) 
(Retrieved from http://www.hearinglosshelp.com/articles/ kindsofhearinglosses.htm on 
August 23, 2013). If a single pattern is present in all members of a family, it can predict 
the locus of the underlying genetic cause. For example the audioprofile of individuals 
with WFS1 non-syndromic hearing loss has a highly characteristic shape (Fig.1.5) (Smith 
et al., 2013). 
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By performing pedigree and audioprofile analyses the list of candidate genes can 
be greatly decreased. This helps the researcher narrow in on the underlying genetic cause 
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Figure 1.3. A graph of hearing threshold – to read this graph you look at the dots 
to see how loud a sound has to be at a specific frequency for the individual to hear 
it. For example at 8000 Hz the individual can only hear sounds louder than 50 dB. 
Therefore the person has trouble hearing high-pitched sounds, so has high 
frequency hearing loss. The red line indicates the threshold for hearing loss. 
When an individual cannot hear sounds above 20 dBHL, they are considered to 
have hearing loss at that frequency. This particular individual does not have 





























Figure 1.4. Sample audiograms. A – Reverse Slope, B – “Cookie-Bite”, C- 
Reverse “Cookie-Bite”, D – Sloping, E – Flat Loss 


























   
	   	  
	  
Figure 1.5. The characteristic audiogram of individuals affected by hearing loss 
often associated with mutations in the WFS1 gene that causes nonsyndromic 
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1.2.1 Nonsyndromic Autosomal Recessive Hearing Loss 
Hearing loss can be divided into SHL and NSHL subtypes. SHL is the diagnosis 
when hearing loss occurs with other clinical conditions or abnormalities. This occurs in 
approximately 30% of diagnosed individuals with over 400 hearing loss syndromes 
having been described, including Usher syndrome (hearing loss along with retinitis 
pigmentosa – loss of peripheral vision and night blindness), Pendred syndrome (hearing 
loss along with thyroid problems), and Jervell and Lange-Nielson syndrome (hearing loss 
along with cardiac dysrhythmia) (Van Camp et al., 1997; Hilgert et al., 2009). 
Nonsyndromic hearing loss is diagnosed when the loss of hearing is the only clinical 
phenotype. Nonsyndromic autosomal recessive hearing loss is generally prelingual 
(present before speech develops), almost exclusively a result of cochlear defects (thus 
sensorineural), and usually more severe than all other forms. This type of hearing loss is 
extremely heterogeneous; as of June 23, 2014, 80 loci have been mapped and 55 genes 
have been identified (Hereditary Hearing Loss Homepage http://hereditaryhearing 
loss.org). Like all autosomal recessive disorders an individual must inherit two mutated 
copies of the gene, one from each parent, to present with the disease phenotype. 
Mutations in genes that are located in the DFNB1 locus, connexin 26 (Cx26) and 
connexin 30 (Cx30), are the cause of 30-50% of this type of hearing loss (Bhalla et al., 
2009). The remaining cases are due to mutations in numerous different genes (Hilgert et 
al., 2008).  
Specifically within the DFNB1 locus, mutations in Cx26, also known as GJB2, 
are the most common underlying cause of AR NSHL throughout the world (Kenneson et 
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al., 2002). Another connexin gene found within this locus and 29 kb away from Cx26 is 
Cx30 (or GJB6) and it is also responsible for many cases of this type of hearing loss. 
Both genes are found on chromosome 13 (13q.11-13.q12) (del Castillo et al., 2002) and 
will be discussed in greater detail. 
1.2.2 The Founder Populations of the island of Newfoundland 
The population ancestry of Newfoundland (current population of 514,536 
residents; Statistics Canada http://www.statcan.gc.ca/) is greatly influenced by natural 
expansion from early English and Irish settlers who came to fish the North Atlantic cod. 
The majority of people from Newfoundland are direct descendants of these first 
immigrants. The unique gene pool of this population is the consequence of a small 
number of founders and genetic drift, especially founder effect, a type of genetic drift that 
occurs when a small number of individuals break off from a larger population and form a 
new colony causing a reduction in genetic variation in the new population due to 
reproductive separation (Griffiths et al., 2002). Many of the immigrants in the 1600s 
settled in coastal regions around Newfoundland to be in close proximity to the fishing 
grounds. Individual fishing villages, locally known as “outports”, were isolated from each 
other by ocean and harsh terrain. Furthermore, marriages between Catholics and 
Protestants were strongly discouraged. The result was a high frequency of inbreeding 
within isolated communities which remained distant from each other, increasing the 
prevalence of specific genetic disorders such as hearing loss (Doucette et al., 2009; 
Rahman et al., 2003; Martin et al., 2000). Other disorders, such as Familial Multiple 
Endocrine Neoplasia Type I (Farid et al., 1980), hemophilia A (Xie et al., 2002), 
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hereditary non-polyposis colorectal cancer syndrome (Froggatt et al., 1999), and familial 
adenomatous polyposis (Spirio et al., 1999) have been recognized to be due to founder 
effects in outport communities in Newfoundland. Extended, multiplex families with 
Newfoundland ancestry present an unprecedented opportunity to uncover the etiology of 
genetic diseases like hearing loss. 
1.2.3 Recurrent Mutations: Founder Mutations vs. Mutation Hot Spots 
Common mutations may be due to either founder mutations or to recurrent 
mutations at hot spots, therefore when a common mutation is discovered it is necessary to 
use haplotype analysis to figure out which type of mutation you have uncovered 
(Romdhane & Abdelhak, 2012). Founder mutations are mutations present in a high 
frequency in a particular population, and the reason for their existence is that the 
mutation was present in one ancestor or a small number of ancestors. Mutation hot spots 
can produce recurrent mutations because they are DNA sequences that are highly 
susceptible to be mutated (Retrieved from http://www.ncbi.nlm.nih.gov /books/ 
NBK5191/ on April 26, 2013). The high susceptibility of a sequence to be mutated can be 
caused by instability, unequal crossing over, or a predisposition to substitutions 
(Retrieved from http://www.ncbi.nlm.nih.gov/books/ NBK5191/ on April 26, 2013).  To 
confirm that a common mutation is due to a founder effect, a method called haplotype 
analysis is carried out. A haplotype is the arrangement of marker alleles found on a single 
chromosome. Marker alleles can be single nucleotide polymorphisms (SNPs) or 
microsatellite markers (also known as short tandem repeats – repeating sequences of 
DNA) that are passed on together through a pedigree (Zhao et al., 2003). Haplotype 
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analysis is a type of genetic test that looks closely at these linked DNA segments and 
shows how the specific genetic information is passed down through pedigrees (Retrieved 
from http://www.ncbi.nlm.nih.gov/books/NBK5191/ on April 26, 2013, Romdhane & 
Abdelhak, 2012). The mutation is considered a founder mutation only if it is located at a 
single haplotype. If the mutation is found on multiple haplotypes it is not a founder 
mutation, and may be due to a mutation hot spot (Romdhane & Abdelhak, 2012). 
1.2.4 Previous Hearing Loss Studies in Newfoundland 
The population of the island of Newfoundland has been the focus of extensive 
hearing loss research for more than fifteen years. In 2001, while studying a six-generation 
Newfoundland family, Young et al. identified a missense mutation (p. 2146 G→A) in the 
WFS1 gene that was causing a dominant form of inherited progressive deafness. The 
mutation was found in all affected members of the family and the link between the 
mutations and hearing loss was supported by haplotype and mutation analysis. This study 
by Young et al. was the first to link a mutation in WFS1 with nonsyndromic hereditary 
hearing loss (Young et al., 2001).  In 2004, Ahmed et al. discovered two recessive 
mutations in the TMPRSS3 gene in a six-generation family from the South Coast of the 
island segregating an autosomal recessive form of early onset hearing loss. The role of 
TMPRSS3 in hearing loss was first described in 1996 (Bonne-Tamir et al., 1996; Veske et 
al., 1996). Ahmed et al. first discovered that hearing loss in the Newfoundland family 
was linked to markers for DFNB8/B10. Sanger sequencing revealed two recessive 
mutations, within TMPRSS3, 207delC and IVS8 + 8insT, the latter being novel. 
Haplotype analysis revealed an apparent founder DFNB8/B10 associated haplotype. It 
	  
	  
	   17 
had previously been assumed that the founder effect of a mutation in the Newfoundland 
population would be high due to the isolation of the island. However, that was not the 
case in this study, which highlights the genetic heterogeneity of deafness, even in a 
founder population. As well, Ahmed et al.’s findings challenged the notion that the 
population of the island of Newfoundland was homogeneous. 
A second (consanguineous) family, located on Newfoundland’s South Coast, 
displayed profound hearing loss inherited as an apparent autosomal recessive trait. The 
underlying cause of this disorder was a novel mutation in PCDH15 (a gene also 
associated with Usher’s syndrome - a syndromic form of hearing loss associated with 
vision impairment, Ahmed, 2001), identified by Doucette et al. in 2009. In this study, a 
genome-wide scan was used to map the hearing loss trait to chromosome 10q21-22, and 
genotyping identified that individuals with a hearing impairment were homozygous for a 
16Mb ancestral genotype that included 44 annotated genes. Sequencing analysis was 
performed and identified the novel V528D missense mutation in PCDH15. This is the 
second study that found a PCDH15 mutation causing nonsyndromic hearing loss instead 
of Usher’s syndrome (Doucette et al., 2009). The first study in 2003, found two missense 
mutations (p.G262D and p.R134G) in PCDH15 causing nonsyndromic recessive hearing 
loss (DFNB23) in two Pakistani families (Ahmed et al., 2003).    
1.2.5 Mouse Models and Hereditary Hearing Loss 
It is difficult to follow the process involved in the formation of the human inner 
ear due to the lack of instruments available for observing the development, as well as the 
lack of cell lines that could be used to replicate the events involved (Chatterjee, 2011). 
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Animal models, particularly mouse models are ideal for studying inner ear development 
and also useful for researching human hereditary hearing loss (Friedman et al., 2007; 
Vrijens et al., 2008), because of the similarity between inner ear structures (Avraham, 
2003). There are 77 deafness genes shared by humans and mice (Retrieved from 
http://hearingimpairment. jax.org/models.html on June 24, 2014). In addition to this, mice 
have a short gestational period, and large litter sizes make it feasible to produce large 
numbers of mutated mice (Avraham, 2003).  Using mouse models, researchers can 
mutate a gene of interest, and then follow the development of the structures of the inner 
ear. Observing the resulting phenotype of the mutant mice provides insight into both the 
normal function of the gene as well as the negative impact of the mutation on hearing 
(Friedman et al., 2007). For example, early studies by Avraham et al. (1995) discovered 
that the gene causing the deafness phenotype in the Snell’s waltzer mouse is Myo6, 
providing a candidate gene to test in human subjects. Myo6 encodes a myosin heavy 
chain protein that is expressed in the inner ear and is required for structural maintenance 
(Avraham et al., 1995). Several years later, Melchionda et al. (2001) discovered the first 
human mutation in the human homologue MYO6 to be associated with hereditary hearing 
loss.  
1.2.6 Types of Mutations that cause Hearing Loss 
Variants in DNA do not always result in a disease phenotype and instead can have 
a positive effect on an organism, giving them a survival advantage. When mutations do 
cause a disease phenotype they are called genetic disorders (Relethford, 2012). There are 
many different types of mutations that have different effects on amino acid codons, so 
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that genetic disorders caused by some mutations may be more severe than the disorder 
caused by other mutations in the same gene. 
One type of variant, called a point mutation, is also known as a single base 
substitution because that is literally what occurs, a single base nucleotide is replaced with 
a different base nucleotide. There are three types of point mutations: neutral, missense, 
and nonsense. A neutral variant causes no change in the amino acid codon and therefore 
is not predicted to have a negative effect on the protein. A missense mutation occurs 
when the new (mutated) base nucleotide results in a new amino acid codon, for example, 
a change of AUA to ACA would change the codon from isoleucine to threonine. A 
nonsense mutation arises when the change of a base nucleotide results in a stop codon. If 
the codon for serine, UCG, was mutated to become UAG, this would be a nonsense 
mutation as UAG is a stop codon, meaning that this is the codon that signals the 
premature truncation of the protein with subsequent drastic effect on the phenotype. 
Another type of mutation is a frameshift mutation; these can be deletions or 
insertions of one or more base pairs that can be detrimental when they occur within the 
coding sequence of genes. In a frameshift mutation the number of bases deleted or 
inserted is not divisible by three. For example, the deletion of five bases or insertion of 
two bases cause the reading frame to shift, altering the amino acid codons that follow the 
insertion or deletion and leads to premature truncation in most cases.  
Other types of large multibase mutations include duplications – when a portion of 
a gene, or an entire gene, is reproduced, inversions – when a segment of a chromosome is 
flipped or reversed, and translocations – when segments of nonhomologous 
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chromosomes are interchanged. These can result in gene fusion where the piece of 
chromosome connects genes or parts of genes that would otherwise be separate. When 
these variants do not cause any noticeable effect on the organism’s phenotype, they are 
said to be benign or nonpathogenic (Powar, 2007).  
To determine the nature of the identified variant, first a literature search is 
conducted to locate the mention of the variant in previous studies, the second step is to 
check the variant in the publicly available SNP/1000 genomes database to determine the 
frequency of the variant in the disorder. If the identified variant was not detected in the 
SNP/1000 genome database, it is considered a novel variant. (Mitchell et al., 2005). If the 
variant is considered novel, the researcher must confirm the pathogenicity of the 
mutation. To determine pathogenicity of a mutation, it is helpful to have access to the 
DNA of other family members, affected and unaffected. By sequencing the DNA of the 
family members, a researcher can get clues as to whether or not the identified variant is 
pathogenic. If the variant is found in all affected family members but not in the 
unaffected members, this is one piece of evidence that the mutation may be causative. If 
the mutation is found in all or many family members regardless of their affection status, 
then it is likely that the mutation is benign. The next step would be to check for the 
mutation in the general population, usually by screening members of the same ethnicity. 
If the variant is not found in a general population screen, and is found in only affected 
members of the family, it is very likely the variant is a causative mutation. If a high 
proportion of the population does have the mutation, it is unlikely to be pathogenic.  
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Another piece of the puzzle is to use prediction programs to determine the impact 
of a variant on the protein. There are several prediction programs available to check the 
probability of a mutation being pathogenic. Such programs include SIFT (retrieved from 
http://sift.jcvi.org/ on March 20, 2012 ) which predicts whether an amino acid 
substitution affects protein function, WebLogo ( retrieved from 
http://weblogo.berkeley.edu/ on March 20, 2012) which generates sequence logos 
showing sequence conservation at specific positions, PolyPhen-2 (Retrieved from 
http://genetics.bwh.harvard.edu/pph2/ on March 20, 2012) which predicts the impact of 
an amino acid substitution on the structure and function of the protein, and PMut 
(Retrieved from http://genetics.bwh.harvard.edu/pph2/ on March 20, 2012)	  which 
predicts the pathogenicity of a mutation based on the protein sequence. Using these 
programs can help determine the pathogenicity of a variant. 
1.2.7 Cochlear Function 
Mutations in the Cx26 gene, within the DFNB1 locus on chromosome 13, cause a 
large proportion of NSHL; the percentage varies depending on the population (Connexin-
Deafness Homepage). In order to discuss the role of connexins in hearing loss, it is 
necessary to understand the function of the cochlea. Function of the cochlear tissues and 
auditory nerve depends on the ionic environment surrounding them within the inner ear, 
more specifically the concentration of potassium, an ion with an important involvement 
in sensory transduction (and all nerve signals throughout the human body). Three fluid 
filled spaces in the cochlea, the scala media (containing endolymph), the scala tympani 
and vestibule (both containing perilymph), are separated by tight junction barriers 
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(Fig.1.7). The scala media is filled with potassium rich endolymph whereas the scala 
tympani and vestibuli are filled with the sodium rich perilymph, with a composition very 
similar to intercellular and extracellular fluid ion concentrations, respectively. Sensory 
transduction is controlled by the endocochlear potential (EP), which is approximately 80 
millivolts (mV) and is generated and maintained by the stria vascularis. The distinct ion 
concentrations in each of the fluid filled spaces are maintained by the tight junction 
barriers between them (Wangermann, 2006).   
The sensory receptors within the inner ear are called hair cells (Fig.1.4). The hair 
cell stereocilia are immersed in endolymph, while the cell body is surrounded by 
perilymph. When a sound travels through the outer ear, it vibrates through the ossicles 
and moves the endolymph and basilar membrane upon which the hair cells sit. The 
receptor potentials are generated by the movement of potassium from the endolymph into 
the hair cells via the stereocilia. This begins a cycle where the potassium moves out of 
the hair cell body into the perilymph and eventually returns to the endolymph via the stria 
vascularis (Kikuchi et al., 2000) (Fig. 1.7).	  
	  
1.2.8 Connexin Hearing Loss 
Connexins are gap junction proteins that regulate ion concentrations and are 
found in many different vertebrate tissues. Daniel Goodenough proposed the name 
connexin in 1974. Before Goodenough isolated the subunit and called it a connexin, J. 
David Robertson hinted at a hexagonal lattice of subunits in 1963 when he isolated the 
subunits from Mautner cells (cells that make up the neural circuit in teleost fish that 
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mediate an escape response) of the common goldfish. He found what he called “honey-
comb-like hexagonal arrays of closely packed subunits” which Goodenough (1975) later 
called connexons (the assembly of six connexin proteins) when he investigated the 
structure of the gap junction of mice hepatocytes using electron microscopy, 
biochemistry, and x-ray diffraction techniques.  The idea that gap junctions are made up 
of subunits, connexons, which further consisted of smaller units called connexins wasn’t 
actually confirmed until 1977 when Makowski and colleagues used x-ray diffraction to 
elucidate the composition of gap junctions (Makowski et al., 1977). They established that 
the connexon was in fact a hexamer composed of molecular protein units (connexins) that 
had a molecular weight between 23-28 kilo Daltons (kDa) and that the connexons in 
plasma membranes of one cell connect to connexons in membranes of an adjacent cell to 
form the gap junction (Fig.1.6). 
The human genome contains 21 different connexin genes (Retrieved from 
http://omim.org/ on August 14, 2011). The first connexins to be named were connexin 32 
(GJB1 OMIM# 304040) and connexin 43 (GJA1 OMIM # 121014) (Beyer et al., 1987). 
The genes were first named for the molecular mass of their protein, for example, 
connexin 32 is approximately 32 kDa , connexin 43 is approximately 43 kDa, etc. This 
method for nomenclature was used for a long time and is still in use today. However, 
once connexin genes were separated into alpha and beta groups based on sequence 
similarities and the overall predicted topological organization (Gimlich et al., 1990), a 
new type of classification was established. Those belonging to the alpha group were 
called “A” and those belonging to the beta group “B”. In addition to this distinction they 
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were called GJ, for gap junction, and given a number identifying the order in which they 
were discovered, e.g. GJA1 is connexin 43.  
Each of the 21 known connexin proteins has been mapped to different areas in the 
human genome (Retrieved from http://omim.org/ on August 14, 2011). These genes are 
developmentally regulated and can be co-expressed in the same cell (Kumar et al., 1992). 
The function of many of the connexin genes and their products has been revealed through 
the study of the effect of mutations within the genes. Mutations in many of these genes 
have been associated with disease. For example mutations in the connexin 32 gene, 
GJB1, underlie Charcot-Marie-Tooth-Disease, a neurological disorder involving 
weakness in the foot and lower leg as well as difficulty with auditory and fine motor 
skills (Bergoffen et al., 1993). Mutations in more than one connexin gene (Cx 26 and Cx 
30) also cause nonsyndromic hearing loss (Pfenniger et al, 2010). 
Within the cochlea both Cx26 and Cx30 are components of gap junction systems, 
which are essential to the cycling of potassium. They form the channels that facilitate the 
constant movement of potassium ions through the hair cells and back into the endolymph, 
an ionic current flow that is undulated by vibration during the transduction of sound into 




















1.2.8 Connexin 26 and Hearing Loss 
	  
Kelsell et al. identified Cx26 as the first autosomal NSHL susceptibility gene in 
1997. The authors realized that the DFNB1 locus and Cx26 mapped to the same location 
on chromosome 13. When they sequenced Cx26 in individuals with a hearing impairment 
from DFNB1- linked Pakistani families, they discovered homozygous substitutions in 
two of the hearing impaired offspring and found their unaffected parents to be 
heterozygous carriers for these mutations. Kelsell et al. also identified mutations in the 
Cx26 gene in other affected members of different Pakistani families, giving them further 
Figure 1.6. Six connexins come together to form a connexon. Connexons are 
located in the cell membranes of cells. When cells come together connexons meet 
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proof that deafness in these families was caused by mutations in Cx26. The authors took 
this to mean that the Cx26 protein is an essential component of the cochlea. We now 
know that Cx26 is expressed in many areas within the cochlea, specifically in the regions 
that separate the scala media from the scala tympani (Retrieve from 
http://hereditaryhearingloss.org on November 23, 2011) (Fig.1.7). The loss of the 
function of Cx26 within the inner ear is expected to disrupt the flow of potassium thus 
interrupting the generation and passage of the electric signal from the inner ear to the 
auditory nerve and onto the brain (Petersen 2012). 
As of June 27, 2014, 111 NSHL mutations have been described within the Cx26 
gene, including splice, nonsense, missense, and frameshift mutations (Retrieved from 
http://davinci.crg.es/deafness/ on June 27, 2014). The most common Cx26 mutation in 
the Caucasian population (Denoyelle et al., 1997), the deletion of a guanine at position 35 
(c.35delG), was first identified by Zelante et al. in 1997 after they sequenced the Cx26 
gene in thirty-five affected patients from the Mediterranean. This mutation causes a 
frameshift that leads to premature chain termination and is found in a region of six 
guanine nucleotides close to the 5′ end of the Cx26 coding region (Zelante et al., 1997).  
Most of the mutations in Cx26 lead to malformed channels, which causes altered 
assembly of hemichannels, disrupted targeting to the plasma membrane, or decreased 


















1.2.9 Connexin 30 and Hearing Loss 
Cx30 (GJB6) is another connexin gene heavily involved in NSHL and is 
associated to hearing loss caused by mutations in Cx26 (retrieved from 
davinci.crg.es/deafness/ on November 24, 2011). Cx30 was first described in the DFNA3 
locus and found to cause autosomal dominant hearing loss (Grifa, 1999). It was 
discovered when 38 families, with hearing loss linked to chromosome 13, tested negative 
for Cx26 mutations (Grifa, 1999). Cx30 maps to chromosome 13q12 and is located near 
(~800kb) connexin 26 (Grifa, 1999). Close to 50 percent of individuals who are 
Figure 1.7. A drawing of the inner cochlea highlighting the areas in which connexin 
26 is expressed. The numbers shaded orange are the areas of expression. These are 
the same areas of expression as connexin 30. (Image taken from Van Camp G, Smith 
RJH. Hereditary Hearing Loss Homepage. http://hereditaryhearingloss.org) 
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heterozygotes for Cx26 mutations also have a large deletion in the Cx30 gene causing 
hearing loss (del Castillo et al., 2003; Mahdieh et al., 2010) 
Many hearing impaired patients with nonsyndromic hearing loss (NSHL) have 
only one mutated allele in Cx26 (del Castillo, 2002). For a long time these individuals 
were considered unsolved because another Cx26 mutation was suspected, but could not 
be found. Even more confounding was that some patients with hearing loss showing 
linkage to DFNB1 were void of mutations in Cx26 (del Castillo, 2002). In 2002, del 
Castillo et al. discovered a 342kb deletion, which they later named Δ(GJB6-D13S1830), 
in the Cx30 gene - a gene known to be co-expressed with Cx26 in the inner ear (Fig.8). 
This discovery was made in 33 unrelated probands affected by hearing loss with 
heterozygous mutations in Cx26. Haplotype analysis was performed using markers on 
13q12 to look for mutations outside of Cx26. Del Castillo et al. found that it was 
impossible to amplify several markers in the vicinity of Cx30 in two of the subjects, 
which led them to believe that the subjects harboured a germline deletion. Upon analysis 
of DNA fragments of Cx30 they discovered that the deletion truncated the open reading 
frame of the gene. The authors were able to determine the break points using sequence 
tagged sites, and they created a specific Polymerase Chain Reaction (PCR) assay to 
detect the Δ(GJB6-D13S1830) deletion (del Castillo, 2002). PCR is a technique that uses 
DNA polymerase to synthesize a new strand of DNA that is complementary to the 
template strand added to the reaction mixture. At the beginning of the reaction the 
mixture is heated to separate the strands of DNA. DNA polymerase then synthesizes the 
complementary strand between specific primers. The mixture is then cooled and the DNA 
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anneals. The cycles of heating and cooling are repeated, thus causing exponential 
amplification of the targeted section of DNA. When the process is completed this section 
of DNA will have accumulated in billions of copies.  The Cx30 deletion truncates the 
protein and is often found in conjunction with a heterozygous mutation in Cx26 in 
hearing loss patients. The discovery of Δ(GJB6-D13S1830) solved a portion of the 
hearing impaired cases that were unexplained up to this point.  
Once del Castillo et al. discovered this deletion they questioned whether the 
pattern of inheritance, where deafness was caused by two heterozygous mutations in two 
different genes, was monogenic or digenic (del Castillo et al., 2002). If it were a 
monogenic pattern (due to a single gene), there would need to be a regulatory element 
upstream of both genes that controlled the expression of Cx26. They reasoned that the 
deletion would suppress gene expression, resulting in hearing loss (del, 2002). A second 
explanation would be that the deletion disrupts the activity of another gene that is 
important for the function of Cx26. Evidence suggests that Cx30 is this other gene that is 
required for Cx26 to function normally (del Castillo, 2002). Del Castillo et al. (2002) 
suggested that the DFNB1 locus contains two genes, Cx26 and Cx30, and altering any 
two of the four alleles will cause hearing loss. Pallares-Ruiz et al. (2002) also suspected 
that this phenomenon represented a pattern of digenic inheritance and tried to determine 
if this was the fact, however their results were inconclusive. It was not until 2009 that a 
group provided conclusive results after testing this hypothesis.  Rodriguez-Paris et al. 
(2009) used allele specific analyses based on reverse transcriptase PCR (RT-PCR) using 
buccal cells that express both Cx26 and Cx30 equally. In the three hearing impaired 
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probands studied, all of whom carried Δ(GJB6-D13S1830), none expressed Cx26 when 
Cx30 had been altered, proving that the Cx26 protein is not produced when Δ(GJB6-
D13S1830) is present in the Cx30 allele. This finding would be expected with the loss of 
a cis-regulatory element found within the deleted region thus disrupting the transcription 














1.2.10 Connexin 31 and Hearing Loss 
 Cx31, located on chromosome 1p34, encodes the human gap junction protein β-3, 
also known as GJB3, and is expressed in the skin, inner ear (specifically the spiral 
ligament, spiral limbus, and the auditory nerve), and the auditory nerve (Fig.1.9). Like 
Figure 1.8. A drawing of the inner cochlea highlighting the areas in which connexin 30 
is expressed. The numbers shaded orange are the areas of expression. Again, notice 
that the areas of expression are the same for connexin 30 and connexin 26. (Image 
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connexin 26 and 30, connexin 31 forms channels called gap junctions in the inner ear that 
allow the movement of potassium ions between the organ of Corti and the endolymph of 
the scala media (Hauwe et al., 1999; Oh et al., 2012).  
 Linkage of Cx31 to hearing loss was first shown in 1998 when Xia et al. explored 
the possibility that other connexin genes (besides Cx26 and Cx30) might be involved in 
the hearing process. They used two multiplex families of Chinese ancestry to map the 
third connexin gene to chromosome 1p33-p35, and used Sanger sequencing to reveal two 
mutations, a missense (c.547 G>A: p.Q183K) and a nonsense (c.538 C>T: p.R180X) 
mutation associated with autosomal dominant, bilateral, high-frequency loss. Using RT-
PCR they showed that Cx31 was expressed in the rat inner ear. 
 Mutations in Cx31 have also been shown to cause recessive hearing loss in a 
compound heterozygous manner (Liu et al., 2000). Liu and his team of researchers 
looked at 25 Chinese families with recessive hearing loss and found that the members of 
two of the families, affected by early onset, sensorineural, bilateral hearing loss, had an 
in-frame 3 base pair deletion (423-425ATT) in one allele causing the loss of an isoleucine 
residue at codon 141 and a c.423A>G transversion (p.I141V) in the other allele. 
Therefore, similar to Cx26, mutations in Cx31 can cause either autosomal dominant or 
autosomal recessive hearing loss (Liu et al., 2000).  
 In 2000, Lόpez-Bigas et al. found five SNPs (c. 1227C>T, c.1610G>A, c.1700 
C>T, c.1731G>A, and c.1931C>T) in Cx31 in patients affected by hearing loss. Two of 
the SNPs, c.1227C>T and c. 1731G>A, cause amino acid changes p.R32W and V200I, 
respectively. The nucleotide change c.1931C>T was found in 24 of the 153 hearing 
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impaired subjects screened, however it was also found in 13 percent of the control 
population. In much the same way p.R32W was found in seven of the 153 subjects with 
hearing loss, but also in 18 percent of the control population. The other three changes 
were not found in the ethnically matched control population; however the amino acid 
change V200I is in an area that is not well conserved, and in the rat and mouse the amino 
acid at position 200 is an isoleucine rather than a valine. The other two SNPs (c.1227C>T 
and c.1610G>A) had no obvious effect on the protein, thus Lόpez-Bigas et al. concluded 
that none of the SNPs found were causative, but would be useful in segregation and 
linkage disequilibrium analysis which can determine the patterns of inheritance.   
 Rouan et al. (2003) used HeLa cells to determine the function of the Cx31 protein 
with a R32W variant. In this case they were investigating the connection between this 
variant and erythrokeratodermia variabilis (EKV), a skin disease that is also caused by 
mutations in Cx31. They transfected HeLa cells with mutated and wild type Cx31 
expression constructs and looked at synthesis, intracellular distribution, and protein 
assembly. The cells with mutated Cx31 showed no deviations in expression level, 
connexon assembly, or intracellular distribution. They concluded that R32W is an 
inconsequential sequence polymorphism of Cx31 (Rouan et al., 2003). 
	  
	  















1.2.11 Digenic Inheritance and the Connexin Genes 
It is now an accepted fact that mutations in two separate loci (genes) can cause 
recognisable patterns of hereditary deafness, known as digenic inheritance. For example, 
in one study it was shown that non-syndromic hearing loss can be caused by digenic 
inheritance of mutations in Cx26 and Cx31 (Liu et al., 2008). This group of researchers 
screened the Cx31 gene in 108 patients from China who were already shown to have 
heterozygous Cx26 mutations and who did not have mutations in Cx30. They found two 
mutations (N166S and A194T) in Cx31 in patients who had either 235delC or 299delAT 
mutation in Cx26; none of the Cx31 mutations were found in the Chinese population 
controls. Because Cx26 and Cx31 have overlapping expression patterns it is likely that 
Figure 1.9. A drawing of the inner cochlea highlighting the areas in which connexin 
31 is expressed. The numbers shaded orange are the areas of expression. (Image 
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these proteins have direct physical interaction (Liu et al., 2008). They also found that 
Cx26 and Cx31 form heteromeric connexons in mouse cochlea leading them to conclude 
that the mutations they found in Cx26 and Cx31 were in fact the cause of hearing loss in 
the patients involved (Liu et al., 2008). 
 Recently Oh et al. (2012) looked for a relationship between variants in Cx31 and 
Cx30 and nonsyndromic hearing loss in the Korean population. Through gene sequencing 
they found a total of nine variants, four of which were novel. They chose five of these 
variants (three novel: Cx31: V27M and V43M, Cx30: A40V, two known: Cx31: V84I, 
Cx30: A40V) to perform functional studies using a pathogenicity prediction program, 
also the area of the mutation was analyzed for conservation (other variants were excluded 
due to the frequency of their occurrence in unaffected individuals). Three of the variants, 
V27M and V84I in Cx31, and A40V in Cx30, were predicted to be deleterious because 
they were not found in unaffected individuals and the residues were highly conserved 
among different species (Oh et al., 2012). As well, using biochemical-coupling tests, two 
of the variants in Cx31 (V27M and V84I) were shown to affect protein function when 
they were present in a heterozygous form with wild type Cx31. The biochemical-coupling 
tests were performed by recording the time it took to diffuse Lucifer Yellow dye from 
cell to cell using cells that contained connexins with heterozygous mutations and WT 
mutations. The times were recorded as either immediate transfer: less than 30 seconds, 
delayed transfer: 30 seconds to 3 minutes, and no transfer: more than 3 minutes. If the 
time was delayed or there was no transfer then it was inferred that the protein was not 
functioning correctly (Oh et al., 2012).  
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 The studies discussed suggest that Cx31 plays a major role in the hearing process 
and mutations in this gene can cause hearing loss in both an autosomal dominant and 
autosomal recessive manner. It has also been suggested that this gene be included in 
hearing loss screening studies along with Cx26 and Cx30 because of the connection 
shown between these connexin genes and hearing loss. 
1.2.12 Mitochondrial Hearing Loss 
Mitochondria are membrane-bound organelles found within most eukaryotic cells 
and are responsible for generating adenosine tri-phosphate (ATP), a molecule that is used 
as a source of chemical energy within the body (Scheffler, 2008; Copeland, 2002). The 
number of mitochondria contained within a cell depends on the organism as well as the 
tissue type and can range from a couple of hundred to a few thousand. Cells within tissue 
that requires a lot of energy to function, like muscle tissue and the inner ear, often contain 
more mitochondria (Scheffler, 2008; Copeland, 2002). 
One important distinction that separates mitochondria from other organelles 
within the cell is that mitochondria have their own genome made up of several copies of a 
double-stranded chromosome that takes the shape of a ring (rather than a helix, as found 
in nuclear DNA) with its own genetic code (Barrell et al., 1979). The human 
mitochondrial genome consists of 16,569 base pairs (Anderson et al., 1981, GenBank,) 
that make up 37 genes: 13 code for the proteins that interact with nuclear proteins to carry 
out oxidative phosphorylation, 22 code for the transfer RNA required for the 
mitochondrial protein-synthesizing system, and 2 code for the large and small subunits of 
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ribosomal RNA (taken from www.ncbi.nlm.nih.gov/genbank/ on November 29, 2011, 
Fischel-Ghodsian, N., 2002).  
The mitochondrial genome is maternally inherited. While both egg and sperm 
contain mitochondria, the mitochondria from the sperm are lost during early 
embryogenesis (Manfredi et al., 1997). Therefore, a mother may pass on any mutations in 
her mitochondrial genome to all of her children.  Determining whether or not the 
mutation will be passed on depends on the number of mitochondrial chromosomes or 
mitochondria that contain the mutation. For example, some mitochondrial mutations are 
heteroplasmic, that is, they are only present within some mitochondria out of all 
mitochondria that are contained in the cell. Other mitochondrial mutations are 
homoplasmic, meaning the mutation is present in all of the mitochondria (Wallace, 
1992). In the case of a heteroplasmic mutation the proportion of wild type or mutant 
genes that are passed on is random. It is possible that a mother will pass on only those 
mitochondria that do not carry the mutation and therefore no phenotype will appear 
(Fischel-Ghodsian, N., 2002).  Mitochondrial mutations are difficult to pinpoint because 
there are numerous DNA molecules within a single mitochondrion and there are 
numerous mitochondria per cell.  
In the early 1990s, it was discovered that mutations in mitochondrial genes were 
linked to hereditary hearing loss (Hu et al., 1991; Jaber et al., 1992; Prezant et al., 1993). 
Hu et al. (1991) analyzed 36 pedigrees with a positive history of aminoglycoside induced 
hearing loss and in 22 of the pedigrees where the pattern of inheritance could be 
ascertained they found that transmission of the predisposition to develop a hearing 
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impairment after aminoglycoside exposure was exclusively through females. They 
considered two explanations for this type of transmission: the first was that it could be an 
X-linked predisposition; the second was that it could be caused by mitochondrial 
inheritance. They ruled out X-linked transmission as there was equal inheritance in 
females and males and the affected males did not pass the predisposition on to their 
daughters or the sons of their daughters. Because they could exclude X-linked inheritance 
this left them with the conclusion that aminoglycoside induced hearing loss was a 
mitochondrially inherited disorder. Hu et al. were the first group to come to this 
conclusion, and at the time there were only a few rare diseases shown to be 
mitochondrially inherited. Following this conclusion, the next step Prezant et al. (1993) 
took was to look for mutations in the human ribosomal RNA (rRNA) genes, which are 
found in mitochondrial DNA, in those families. The investigators chose this area to begin 
their mutation search because they knew that the rRNA of bacteria was the target of these 
antibiotics. As well, they decided to sequence the entire mitochondrial genome in a large 
Arab-Israeli family. Each of the four families had a substitution of a guanine for an 
adenine at position 1555, within the 12S rRNA gene. This was the first case of a 
mitochondrial mutation being associated with non-syndromic hearing loss. It was 
discovered that the A1555G mutation in the mitochondrial gene MTRNR1was one of the 
most frequent causes of hearing loss after mutations in Cx26, and SLC26A4 (Solute 
carrier family 26 member 4, the gene mutated in Pendred syndrome – deafness with 
thyroid enlargement, and in DFNB4 with enlarged vestibular aqueduct; taken from 
http://omim.org/ on February 13, 2012; Guo et al., 2008).  
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Since the early 90s, many families have had their hearing loss explained by 
mutations in mitochondrial genes. As well, in the case of aminoglycoside-induced 
hearing loss, it is possible to prevent the development of a hearing impairment by 
avoiding aminoglycoside antibiotic therapy in individuals with a family history of 
aminoglycoside induced hearing loss (Hu et al., 1991; Selimoglu, 2007). There are now 
two mitochondrial genes associated with NSHL (Retrieved from 
http://hereditaryhearingloss.org/ on November 25, 2011). Neither of these genes are 
protein coding; one, MTRNR1, codes for 12S ribosomal RNA, the small subunit of 
mitochondrial ribosomes that binds with the large subunit, 16S, to carry out protein 
synthesis within the mitochondria. The second, MTTS1, codes for the serine (UCN) 
transfer RNA, the RNA that carries serine to the polypeptide chain during protein 
synthesis when it is coded for by the triplet AGN (OMIM, http://omim.org/). There are 
three mutations in MTRNR1 that are associated with both aminoglycoside-induced 
hearing loss and NSHL that is not triggered by aminoglycoside exposure. There are four 
mutations reported to cause nonsyndromic hearing loss in MTTS1, however two of these 
mutations are also associated with another disorder. The c.7445A>G mutation is 
associated with palmoplantar keratoderma (PPK) and the c.7472insC mutation is 
associated with neurological dysfunction, including ataxia, dysarthria and myoclonus 
(Hereditary Hearing Loss Homepage http://hereditaryhearingloss.org/).  
The first of these mitochondrial mutations to be associated with hearing loss was 
discovered in an Israeli-Arab pedigree with hearing loss inherited through the maternal 
line (Jaber et al., 1992; Prezant et al., 1993). The hearing loss was progressive and 
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usually presented in childhood.  It was Prezant et al. in 1993 that sequenced the entire 
mitochondrial genome of family members from the Israeli-Arab pedigree and also from 
three unrelated patients with familial aminoglycoside-induced deafness. They found a 
point mutation at position 1555 that changed an adenosine to a guanine in the gene that 
codes for the 12S ribosomal RNA (rRNA). This mutation was shared amongst all four 
families. However, Prezant et al. were not the first to suggest that familial 
aminoglycoside-induced deafness was caused by a defect in the mitochondrial DNA. In 
1989, Higashi looked at 28 Japanese families to determine whether males or females 
passed on the trait of susceptibility of streptomycin deafness. After examining each 
pedigree he concluded that it was in fact transmitted through only females. Until this 
discovery, the susceptibility of the cochlea to streptomycins was assumed to be 
autosomal dominant (Higashi, 1989). Higashi (1989) also suggested that because familial 
hearing loss induced by streptomycin exposure could not be explained by ordinary 
Mendelian inheritance, then ototoxicity caused by streptomycin intake somehow 
disrupted ATP production in the mitochondria of the hair cells, and that might be caused 
by changes in the mitochondrial DNA.  
Once the A1555G mutation had been discovered in aminoglycoside induced 
deafness it was also found to cause nonsyndromic hearing loss worldwide, in Arab-
Israeli, Japanese, Mongolian, Zairean, Spanish, Chinese, Turkish, and Balinese families 
(Usami et al., 1997; Estivill et al., 1998; Kupka et al., 2002; Abreu-Silva et al., 2006; 
Kokotas et al., 2009). In fact mutations in connexin 26, SLC26A4, and mtDNA A1555G 
are the most prevalent causes of deafness worldwide (Guo, 2008). This means that 
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screening for the mtDNA A1555G mutation should be included when looking for the 
underlying genetic cause of hearing loss in a family, especially if the inheritance appears 
to be maternally transmitted or hearing loss occurred after aminoglycoside use.   
The first mutation identified in MTTS1 changed an adenosine at position 7445 to a 
guanine. It was found by Reid et al. in 1994 in all affected members of a family with 13 
members displaying sensorineural NSHL. The second MTTS1 mutation was an insertion 
of a cytosine at position 7472, found by Tiranti et al. in 1995 after sequence analysis of 
the tRNA gene regions of mitochondria in affected individuals from a large Sicilian 
kindred. This mutation causes nonsyndromic hearing loss as well as hearing loss 
accompanied by ataxia and myoclonus (Tiranti, 1999).  The third MTTS1 mutation found 
to cause hearing loss was the change of a thymine to cytosine at position 7511 (7511 
T>C), a mutation discovered by Sue et al. in 1999 in 36 affected members of a large 
African American family when they sequenced the entire mitochondrial genome in 
search of mutations because of the maternal transmission of hearing loss. This mutation, 
which disrupts a highly conserved site in the mitochondrial DNA, was determined by Sue 
et al. (1999) to be pathogenic. The fourth MTTS1 mutation found thus far is a change 
from thymine to cytosine at position 7510 (7510 T>C), and was identified in a Caucasian 
family by Hutchin et al. in 2000. Hearing loss in this family appeared to be transmitted 
through the maternal line so they looked for mutations in the mitochondrial DNA. First 
they screened for other known mitochondrial DNA mutations, but all were absent. They 
then found the T to C transition at base pair position 7510. This novel thymine to 
cytosine transition at position 7510 was found in all affected family members and was not 
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found in 141 Caucasian controls. As well the thymine at position 7510 is highly 
conserved in a wide range of species (Hutchin, 2000).  These mutations in the MTTS1 
gene should also be included when screening for genetic hearing impairment, especially 
in families where hearing loss is transmitted through the maternal line. 
1.3 Summary 
Hearing loss is a very debilitating disorder that causes many problems in a 
developing child. If hearing loss is pre-lingual, a child will have difficulty learning to 
speak, as children acquire this ability by imitating sounds they hear around them, such as 
the voices of parents and siblings. The longer hearing loss remains undetected the greater 
the likelihood for permanent impairments of speech and language that are necessary for 
social development and the ability to take part in a standard education system (NIDCD 
website). Through the study of hearing loss genetics, the underlying causes of inherited 
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2.Materials and Methods 
2.1 Subject Recruitment 
	  
Probands with hearing impairment, along with their relatives, were recruited from 
across Newfoundland and Labrador. This study focused on predominantly probands with 
profound hearing loss as children. Probands and their blood relatives were recruited to the 
study through various poster drives and through the Provincial Medical Genetics Program 
of Eastern Health, St. John’s. Family history, informed consent, and permission to access 
medical records and audiograms were obtained as per approved protocol #01.186 
(Human Research Ethics Board, St John’s, NL, Canada). The team also collected 
information on the geographical location of family founders. The patients and/or their 
parents/guardians completed a hearing loss questionnaire (Appendix 2), and a blood 
sample for DNA isolation was obtained from all available family members. Probands 
with hearing impairment due to known environmental factors such as infection and 
acoustic trauma were excluded from further study.  
2.2 Overall Design of Candidate Gene Approach 
 
A step-wise, targeted screening approach was used to look for mutations across 
three categories of deafness genes: (1) genes with mutations previously identified in 
hearing impaired probands with Newfoundland ancestry; (2) genes frequently mutated in 
Caucasians with hearing loss, and (3) genes that cause specific, recognizable patterns of 
hearing loss as seen on an audiogram.  When a pathogenic mutation was identified in a 
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proband, I confirmed, where possible, which side of the family the mutation came from 
by genotyping DNA from the parent(s) and other available blood relatives. 
 (1) Screening genes identified in hearing impaired probands from Newfoundland 
Preceding this study, working as a Research Assistant in Dr. Young’s laboratory, 
I screened 77 probands for mutations in genes previously found to cause hearing loss in 
the Newfoundland population; namely WFS1, TMPRSS3 and PCDH15 that our lab 
previously identified in deaf probands from Newfoundland (Young et al., 2001; Ahmed 
et al., 2004; Doucette et al., 2009) and for common mutations causing hearing loss in 
Cx26 and Cx30. The analysis of this data is part of my thesis project. In order to detect 
potential recurrent mutations due to founder effects in the Newfoundland population and 
potentially (and efficiently) solve one or more probands for my thesis project I also 
sequenced genomic DNA of 33 newly ascertained probands for mutations in WFS1, 
TMPRSS3 and PCDH15.  
(2) Screening Genes identified in Caucasians with Hearing Loss 
In order to detect common mutations in the Cx26 and Cx30, two different protocols were 
required. To detect the common point mutations in Cx26, full, bidirectional Sanger 
sequencing of Cx26 was done on DNA from the newly ascertained probands (n=33).  
However, Sanger sequencing is not sufficient to detect the common mutation in Cx30, as 
it is not a point mutation but a large deletion. Therefore, a PCR-based method, first 
described by del Castillo et al. (2002), was used to detect the common 342 kb deletion 
(del13S1830) in Cx30 in the newly ascertained probands (n=33).   
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The next step was to look for common mutations that occur in the mitochondrial genome 
that can also lead to hearing loss. To do this, mitochondrial DNA from all unsolved 
probands (n=101/110) was screened for mutations in the mitochondrial genes MTRNR1 
and MTTS1 using full, bidirectional Sanger sequencing.  
 (3) Screening Genes Causing Recognizable Audiogram Patterns (Audioprofiles)  
In some cases, the underlying causative gene can be suggested by patient 
audioprofiles, or pattern of loss as seen on an audiogram. For the majority of probands in 
this study, at least one audiogram was available and the audiograms were analyzed and 
grouped into four categories (low-frequency loss, mid-frequency loss, high-frequency 
loss and flat loss; Figure 2.2).  
2.3 Techniques for Mutation Detection 
1. Extraction of Genomic DNA 
Genomic DNA was extracted from the blood of affected probands and their 
relatives and archived and stored at 4°C. For the 33 new recruits, I extracted genomic 
DNA from peripheral blood (leukocyte fraction) according to a standard salting out 
protocol (Appendix 3). 	  
2. Amplification of Targeted Sequences by Polymerase Chain Reaction (PCR)  
PCR reactions contained 1X Kapa Taq Buffer A with 1.5 mM MgCl2 (Kapa 
Biosystems, Woburn, MA), 0.9 M betaine (Sigma, Saint Louis, MO) 0.2 mM dNTPs 
(Applied Biosystems, Warrington, UK), 0.4 uM of each primer (IDT, San Diego, CA), 
0.4U of Kapa Taq, and 10 ng of purified DNA in a total volume of 20 µL. This master 
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mix was used for all genes with the exception of Cx26.  The master mix for Cx26 did not 
contain betaine. PCR was performed on a GeneAmp PCR System 9700 thermocycler 
(Applied Biosystems, Foster City, CA) with cycling conditions of [94oC/ 5 min, (94oC/ 
30 s, 640C – 2.00C per cycle/30 s, 720C/ 30 s) x 5 cycles, (94oC/ 30 s, 54oC/ 30 s, 720C/ 
30 s) x 30 cycles, 720C/ 7 min]. The primers and amplification conditions for each gene 
are provided in Appendix I. The PCR products were stained and run on a 1% agarose gel 
(0.5g agarose/ 50mL 1X TBE + 2.5µL SYBR safe/ 50mL of 1X TBE) using gel 
electrophoresis, and viewed with UV light using the Kodak Molecular Imaging system. 
This allowed the product size of the PCR products to be compared to a standard DNA 
ladder in order to be sure the anticipated size of DNA segment (PCR product) was 
obtained.	  
3. Preparation for Sanger Sequencing using ABI Cycle Sequencer  
Samples were prepared according to standard lab protocols: 300µL of Sephacryl 
300 was added to each well of a 96 well, 0.45 µm MultiScreen filter plate and centrifuged 
for 5 minutes at 1800 x g. The flow-through was then discarded. Next, the PCR products 
were added to the wells of the MultiScreen plate. A 96 well PCR catch plate was placed 
beneath it and the plates were centifuged at 1800 x g for 5 minutes. This time the flow-
through was retained in the PCR plate and the purified PCR product was prepared for 
sequencing.  
A sequencing master mix was prepared to contain the following ingredients: Sequencing 
Mix (0.5µL), 5X Sequencing Buffer (2.0µL), Primer (either forward or reverse) at 1.6 
mM (2.0µL), and dH2O (14.5µL). This mixture was the same for all genes and yielded 
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19.0µL volume per well of a sequencing plate. 1 µL per well of purified PCR product 
was added to the master mix and then centrifuged briefly and placed on a thermocycler 
for cycle sequencing with cycling conditions of [(96oC/ 1 min, 96oC/ 10 s, 500C/5 s, 60oC/4 min) 
x 24 cycles, 40C hold]. 
The next step was ethanol precipitation of the PCR product. 5.0 µL of EDTA 
(125mM) followed by 65 µL of ethanol (95%) were added to each sample in the 
sequencing plate. The plate was then covered and placed at room temperature in the dark 
for 30 minutes to 24 hours to precipitate the DNA. Next, the plate was centrifuged for 30 
minutes at 3000 rpm. The plate was then inverted to decant the ethanol and while still 
inverted was centrifuged briefly at 200rpm to further decant the ethanol. 150.0 µL of 
ethanol (70%) was then placed in each well. The plate was centrifuged for 15 minutes at 
3000 rpm and inverted to decant the ethanol, and then the inverted plate was briefly 
centrifuged at 200 rpm to remove residual ethanol. The plate was left to dry in the dark 
for 10-15 minutes to evaporate any remaining ethanol and dry the DNA pellets. The 
DNA was dissolved in 15.0 µL of HDF (High-Dye Formamide), centrifuged briefly, and 
placed on the thermocycler for denaturing (2 mins at 95ºC).  
Automated sequencing was performed on the Applied Biosystems 3130xl Genetic 
Analyzer (Applied Biosystems, Foster City, CA). The raw sequencing data was inspected 
to check the quality and then analyzed with Mutation Surveyor DNA Variant Analysis 
Software V4.0.6 (State College, PA), which identifies sequence variants in the sample by 
comparing the sample sequence to a reference sequence.  
	  
	  
	   48 
4. Connexin 30 Primers and Conditions for Detecting 342kb Deletion 
The Cx30 gene contains a 342kb deletion that has been associated with hereditary 
hearing loss (del Castillo et al., 2002).  Detection of this deletion is different from the 
detection of other, mainly point mutations in this study. Rather than using Sanger 
sequencing, the presence of a deletion is detected by analyzing band sizes of the PCR 
products on an agarose gel. The forward and reverse strands of a segment of Cx30 were 
amplified to detect the large 342kb deletion (del13S1830) (del Castillo et al., 2002). Two 
primer sets were used according to the del Castillo protocol; the first primer set, called 
“Connexin 30 c” (Appendix 1, Table 1), will amplify a 651 bp segment of the intact Cx30 
gene (when there is no deletion). If the 342kb deletion mutation is present, the reverse 
primer cannot bind, resulting in no PCR product. The second primer set “Connexin 30 d” 
has a forward primer and reverse primer that anneal at opposite ends of the gene 
(Appendix 1, Table 1).  In a normal gene sequence, these primers lie too far apart to 
produce a PCR product. However, the large deletion mutation in Cx30 removes 342kb of 
sequence and by doing so, brings the forward and reverse primers in close enough 
proximity to each other to produce a PCR product (405 bps). This approach provides a 
positive test for the detection of the deleted allele.  
In order to carry out the PCR test for the Cx30 deletion mutation, the four primers 
were combined (0.2µM each) into one PCR mixture (0.4 µL each). The other reagents in 
the PCR mixture include: 10x Buffer with Mg2+ (2.0µL), dNTPs (2mM; 2.0µL), Taq 
Polymerase (0.08µL), betaine (4.0µL), and dH2O (9.32µL). This 19.0 µL total volume 
was multiplied according to the number of samples being tested. The mixture was 
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aliquoted into wells on a PCR plate along with 1.0 µL of DNA and placed in a 
thermocycler for amplification (see Appendix 1,Table 1 for cycling conditions). 
The sizes of the PCR products were determined after they were separated by 
electrophoresis through a 1% agarose gel (0.5g agarose/ 50mL 1X TBE + 2.5µL SYBR 
safe/ 50mL of 1X TBE).  The genotype of each proband at the Cx30 locus was easy to 
determine with this PCR-based test. The normal sequence produces a PCR product 651 
bps in size. A sequence with the deletion produces a PCR product of 405 bps (del Castillo 
et al., 2002). A proband with two copies of the normal (undeleted) Cx30 gene would 
yield a single 651 bp band; a proband heterozygous for the deletion would yield two 
bands (one 651 bp and one 405 bp); an individual homozygous for the deletion mutation 
would yield a single 405bp band. 
5. Detection of a Possible Mitochondrial Deletion  
 Because mitochondrial traits are passed down maternally and can appear to be 
transmitted in a dominant or recessive manner, at this stage of the targeted screening 
protocol, it was prudent to screen all unsolved probands for potential mutations. Three 
sequencing primer pairs were designed to overlap each other in order to fully cover the 
MTRNR1 gene, and one primer pair was designed to cover the MTTS1 gene (Appendix I). 
For example, the first primer pair for MTRNR1 covered positions 133 to 941, the second 
primer pair covered positions 614 to 1463, and the third pair covered positions 1273 to 
1771. These position numbers indicate the position within the circular mitochondrial 
genome.  The PCR products, using primers 133F-941R, were examined by gel 
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electrophoresis to check for the correct product size. For a normal MT sequence, the 
expected band size is approximately 800 bps.  
5. Verification of Pathogenicity 
There are several steps to help verify if a variant is pathogenic, that is, causative for 
deafness. Mutations were deemed pathogenic if a literature search of high quality 
publications revealed strong evidence that the mutation was pathogenic. For novel 
variants, they were also tested for co-segregation with hearing loss in the proband’s 
extended family. The published frequency of the mutation was determined from the SNP 
database, and by genotyping population controls of unaffected individuals with 
Newfoundland ancestry. Furthermore, the predicted effect on the protein was estimated 
using five bioinformatics programs including SIFT, Polyphen, SNPs3D, PMut, and 
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Figure 2.2. Steps of the process of AudioGene candidate gene determination and analysis 
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3. Results 
	  
A candidate gene approach, using a step-wise strategy, was developed to identify 
the genetic cause of hearing loss in 110 probands. The candidate gene approach began 
with 33 newly recruited probands.  These new recruits to the study were first screened for 
deafness mutations identified in the Newfoundland population by our lab. Following this 
screening, all unsolved probands were combined with the 69 unsolved probands from our 
previous studies for a total of 101 unsolved probands (Fig. 3.1). 
3.1 Screening for deafness mutations previously identified in Newfoundland 
	   	  
	   Direct, bidirectional Sanger sequencing of the amplicons covering pathogenic 
mutations in three genes, WFS1 (8 exons), TMPRSS3 (13 exons), and PCDH15 (35 
exons) all yielded high quality sequences for each of the 33 samples (Fig. 3.2). However, 
none of the 33 probands were heterozygous or homozygous for the 3 known deafness 
mutations. In other words, all samples yielded a normal sequence indicating that hearing 
loss in the probands is not due to deafness mutations previously identified in patients with 
Newfoundland ancestry. 
3.2 Screening genes identified in Caucasians with hearing loss 
	  
 The next step in the strategy was to carry out Sanger sequencing on exons 
covering recurrent mutations in populations with similar ancestry to the Newfoundland 
population. For this step, I screened the NL probands for gene mutations known to 
frequently underlie hearing loss in patients of Northern European decent.  
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3.2.1 Probands with variants in connexin 26 and connexin 30 
	  
For the 33 newly ascertained probands, full gene sequencing of Cx26 was carried 
out. As Cx26 has only two exons, one of which is coding, screening this entire gene was 
straightforward.  Screening of both exons of Cx26 across the 33 samples yielded 30 
normal sequences and 3 mutated sequences. I detected 2 variants, a single base pair 
deletion and common pathogenic mutation causing nonsyndromic hearing loss (Fig. 3.3). 
The deletion of one guanine in a chain of six guanines in Cx26 causes a reading 
frameshift in the sequence. Figure 3.3 shows the typical pattern that is seen on an 
electropherogram in a person carrying one copy of the 35delG mutation.  
The second variant detected in the Cx26 gene was a missense mutation, 
c.250A>AG, p.F83L, determined to be nonpathogenic following bioinformatics analyses 
including SIFT, Polyphen, SNPs3D, PMut, and Weblogo. A literature search also 
revealed that the F83L variant was considered to be nonpathogenic in other studies. 
(Retrieved from http://davinci.crg.es/deafness/index.php on October 13, 2010).  
Screening for the Cx30 deletion was not done by Sanger sequencing, but rather by 
examining PCR products (del Castillo et al., 2002). The deletion spans 342 kb and is 
therefore too large to be detected using Sanger sequencing. Instead, the deletion can be 
detected using a set of four primers designed by del Castillo et al. (2002) to amplify the 
truncated construct that results from the deletion. The first set of primers will only 
amplify a 651bp region in the absence of the deletion, this is because the reverse primer 
is designed to anneal to the new sequence that is created in the region of the repaired 
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chromosome. The second set of primers will amplify a 405bp region when the deletion is 
present; otherwise the primers lay too far apart on chromosome 13 to allow for 
amplification. Both amplicons can be distinctly identified on an agarose gel (Fig. 3.4). 
Although it took several attempts to get all samples to amplify, eventually all 33 samples 
worked. Of the 33 samples, 1 sample was positive for the Δ(GJB6-D13S1830) deletion.  
 The Cx26 mutation, c.35delG, and the Δ(GJB6-D13S1830) deletion in Cx30,  
were both identified in the proband from Family 2155 (Fig.3.5), a singleton family. 
Together this digenic inheritance of recessive mutations cause hearing loss, that is, the 
proband is heterozygous for the c.35delG mutation in Cx26 (Fig.3.3) and heterozygous 
for the Δ(GJB6-D13S1830) deletion in Cx30 (Fig.3.4). According to the family history 
data, the parents are unaffected. Therefore, the proband may have a recessive form of 
hearing loss, or alternatively, the hearing loss is due to two de novo mutations, or one 
segregating mutation and one de novo, although both of these latter possibilities are less 
likely. Because there was no DNA available for the parents, I was not able to determine 
which parent carried which mutation, or if either of the mutations were in fact, de novo 
mutations.   
The proband from family 2197 (Fig.3.6) was found to be heterozygous for the 
c.35delG mutation in Cx26 (Fig.3.7). The proband had an affected father as well as two 
affected uncles. The paternal grandmother was also affected, suggesting that hearing loss 
was segregating as a dominant trait on the paternal side. However a second mutation was 
not found in Cx26 or Cx30, and there is no further information or DNA available for 
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other members of the family. Although there are mutations in Cx26 that cause dominant 
nonsyndromic hearing loss, 35delG is not one of them (Retrieved from 
http://davinci.crg.es/deafness/index.php on October 9, 2014). 
Family 2091 has three affected members, the proband (III-11), a paternal cousin 
(III-1), and paternal grandfather (I-1), with no evidence of vertical transmission, making 
the inheritance of hearing loss in the proband appear to be recessive (Fig.3.8). DNA was 
only available for the proband who was identified to have a variant in Cx26, a single base 
pair substitution leading to a missense mutation (c.250A>AG) causing the change of a 
phenylalanine to a leucine (p.F83L) (Fig. 3.9). Using SIFT, Polyphen, SNPs3D, PMut, 
and Weblogo, this polymorphism was predicted to be benign (Table 1, Fig 3.10).  
 
3.2.2 Probands with variants in MTRNR1 and MTTS1 
 
The A1555G mutation in mitochondrial gene MTRNR1 is one of the most 
frequent causes of hearing loss after mutations in Cx26 (Guo et al., 2008), therefore it 
was important to include screening of mitochondrial DNA in this study. In addition, I 
decided to screen the MTTS1 gene because it is the only other mitochondrial gene in 
which mutations are known to cause nonsyndromic hearing loss (Retrieved from 
hereditaryhearingloss.org on September 1, 2014). Screening of mitochondrial genes 
MTRNR1 and MTTS1 was carried out on 101 probands, in two rounds. In the first round, 
twenty probands were screened to perfect the mitochondrial screening process. Full gene 
sequencing was completed for both genes, and six polymorphisms (Guaran et al., 2013; 
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Li et al., 2004) (Table 2) were found in MTRNR1, however no mutations were identified 
in MTTS1.  
The G951 variant, the change from a guanine to an adenosine at position 951, was 
identified in this group in one proband, family 2167 (Figs.3.11 and 3.12). This variant has 
been reported in literature, however its current status is nonpathogenic (Elstner et al., 
2008).  
There were 81/101 probands included in the second stage of screening (Fig.2.1), 
which began when mitochondrial sequencing was perfected and included the remaining 
unsolved probands. In addition to the six polymorphisms identified in the 20 probands 
screened in the first round, two polymorphisms were found (G709A and T1243C) in 
MTRNR1. Two probands, one from each of family 2112 and family 2144, (Figs. 3.13 and 
3.14), were found to carry the homoplasmic A1555G mutation (Figs.3.15 and 3.16), 
known to cause hearing loss following exposure to aminoglycosides (Guan, 2011). 
 
3.2.3 Challenges with Mitochondrial Screening 
Analysis of the first section of MTRNR1 indicated that the proband from family 
2072, as well as the proband’s mother (Fig.3.17), had a lower molecular weight amplicon 
than expected, as seen on the agarose gel (Fig.3.18). This could be interpreted as a 
deletion; however there was no clear evidence of a deletion, i.e., a frameshift in the 
sequence, upon sequencing the truncated PCR product. For reasons unknown, the quality 
of the sequencing was poor up to position 580 in the mitochondrial genome. Upon 
examining these results with Mutation Surveyor®, it was noticed that the sequence of the 
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MTRNR1 forward primer was showing up in the reverse sequence, however it was 
349bps downstream from where this sequence should be, according to the reference 
sequence. The forward sequencing primer was designed to sequence position 133 of the 
mitochondrial DNA onward (Fig. 3.19).  
A second attempt was made to sequence across this region in the probands’ MT 
genome. In order to do this, I designed a new primer set. This approach was successful, 
and after sequencing with the new primers, I discovered that there were two SNPs 
(C150T and T152C) where the 3’ end of the original forward primer was expected to 
anneal at position 133, which explains why the sequence was initially poor and why the 
amplicon for these individuals was much smaller.  
 Once the SNPs, C150T and T152C, were discovered in the proband from family 
2072, the agarose gel for the original MTRNR1 primer set was re-analyzed and it was 
found that a second proband, from family 2010 (Fig.3.20), had the same unusual lower 
molecular weight amplicon. I subsequently screened this second proband, along with five 
of her relatives, for the two control region SNPs (C150T and T152C). Because mtDNA is 
only passed down through the maternal line, as expected, all maternal relatives of the 
proband had these SNPs (C150T and T152C), and a paternal uncle had a different 
haplotype. These results help to validate the utility of my newly designed MT sequencing 
primers and confirm my suspicions regarding the unusual findings.  
 Following the successful re-sequencing of family 2010, all probands in the study 
were screened for these interesting SNPs and a table was created in order to compare the 
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mitochondrial haplotypes of all deafness probands (Table 3). From this exercise, I could 
see that only Families 2072 and 2010 carried C150T and T152C in their MT genomes.  
I then reasoned that if these families are related, it is also reasonable that hearing loss 
might be due to the same underlying genetic etiology. Therefore, I compared the 
audiograms of affected members across the two families (persons III-1, II-4 from family 
2072; person XI-7 from family 2010; Fig.3.21) and submitted the audiograms to 
AudioGene (Retrieved from http://audiogene.eng.uiowa.edu/ on May 8, 2011). The first 
gene predicted to underlie the pattern of hearing loss was KCNQ4. I sequenced the entire 
coding sequence and exon/intron boundaries of KCNQ4 in these individuals, however no 
variants were found. In a similar fashion, other families with similar mitochondrial 
haplotypes were considered together.  Table 3 depicts probands who have matching 
haplotypes. Potentially, the probands with matching haplotypes are linked on the 
maternal side of the family. The blank spaces in Table 3 indicate where multiple 
sequencing attempts failed to identify the correct nitrogenous base. 
3.3 Screening genes causing recognizable audiogram patterns (audioprofiles) 
 From the unsolved probands (n=99), audiograms from 55 probands were 
compared and grouped into four hearing loss categories: low frequency loss, mid 
frequency loss, high frequency loss, and all frequency loss - flat line (Table 4). 
Audiograms were submitted to AudioGene for a potential match to a candidate gene(s). 
In the high frequency category, which included 29 families, five candidate genes (Cx31, 
KCNQ4, MYO6, COCH, and TMC1) were identified as potential targeted genes by 
AudioGene. In the mid frequency category, only one gene (TECTA) was predicted. For 
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the low and flat categories, three candidate genes (WFS1, POU4F3, and DIAPH1) were 
indicated. 
Bidirectional Sanger sequencing of the 29 probands with high frequency hearing 
loss was done for Cx31, KCNQ4, MYO6, COCH, and TMC1 and revealed a total of five 
variants. Two variants were identified in Cx31: c.109G>A, p.V37M and c.94C>T, 
p.R32W, three were identified in TMC1: c.421C>T, p. R141W; c.545G>A, p.G182D; 
and c.1763+3A>G (Table 5). 
Of the two variants found in Cx31, the c.94C>T: p.R32W has a frequency of 
0.015 in the SNP database (Retrieved from http://www.ncbi.nlm.nih.gov/ projects/SNP/ 
on July 15, 2014). This mutation was heterozygous in the proband from each of six 
families: family 2155 (Fig. 3.5), family 2176 (Fig 3.11), family 2078 (Fig. 3.22), family 
2075 (Fig. 3.23) and family 2097 (Fig. 3.24), family 2156 (Fig 3.25). The proband from 
family 2083 carried a single copy of the c.109G>A:p.V37M variant, a novel mutation 
(Fig. 3.26). The proband from family 2083 is also heterozygous for the Cx30 deletion 
∆(GJB6-D13S1830). Screening of the available family members of these probands 
(families 2078, Fig 3.27; 2075, Fig 3.28; 2097, Fig. 3.29; and 2083, Fig. 3.30) revealed 
that the all of the mutations segregated with hearing loss. 
Heterozygous mutations in TMC1 were detected in 3 probands with high 
frequency hearing loss. The R141W missense mutation was found in the proband from 
family 2010 (who also has mutations in the mitochondrial DNA as previously mentioned) 
(Fig.3.20), the G182D in the proband from family 2124 (Fig. 3.31), and c.1763+3A>G in 
the proband from family 2065 (Fig. 3.32).  
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Following the successful screening of high frequency hearing loss families, the 
rest of the unsolved deafness families were also screened for these newly found 
mutations, and subsequently, three more probands were identified with the heterozygous 
c.421 C>T, p. R141W mutation in TMC1: Family 2146 (III-6; Fig.3.33), Family 2177 
(IV-2; Fig. 3.34) and Family 2092 (III-4; Fig. 3.35). Cascade sequencing revealed 3 other 
family members in 2010 (Fig. 3.20) with the heterozygous R141W mutation and 3 other 
family members in 2092 (Fig. 3.35) with the heterozygous R141W mutation. 
Population screening for the three TMC1 mutations produced the following 
results: c.421 C>T p.R141W (dbSNP frequency of 0.001) was found in 2 out of 134 or 
1.5% of alleles in ethnically matched population controls, which falls slightly above the 
boundary for being considered a rare variant (<1% population frequency). The variant 
c.545 G>A p.G182D was not found in dbSNP and was absent in 94 alleles of ethnically 
matched population controls, leading to the belief that it could be a rare variant and 
c.1763+3A>G was not present in dbSNP was absent in 102 alleles in ethnically matched 
population controls, again, evidence that it could be a rare variant. All findings are 
indications that the detected variants are likely pathogenic. 
3.5 Summary of Results 
	  
Several significant findings came out of this research project. First of all, it was 
discovered that mutations previously identified in the NL population were not found in 
any of the probands included in this study. This would lead me to believe that these NL 
mutations are not founder mutations. If they were, I would expect them to be identified in 
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a higher number of hearing impaired probands in the population. Instead these mutations 
seem to be isolated to distinct families.  
Secondly, both the 35delG mutation in Connexin 26 and the large deletion, del13S1830, 
in Connexin 30 were found in two of the probands. One proband was found to be 
heterozygous for both mutations (35delG and del13S1830), known as digenic inheritance, 
causing hearing loss. One proband was a carrier for the 35delG mutation in connexin 26. 
These mutations are the most common cause of early onset hereditary hearing loss in 
Northern European populations. These findings would be expected as many families in 
the current population have Northern European heritage.  
In addition to this, several variants were identified following audiogram analysis and 
candidate gene identification using AudioGene. Two variants were found in Connexin 
31, one known variant (R32W), and one novel variant (V37M) which appeared to 
segregate with hearing loss in four families. Three novel variants were found in TMC1 
(R141W, G182D, and c.1763+3A>G), these variants were not found in high frequency in 
ethnically matched population controls. 
This study also identified two individuals who had the A1555G mutation in the MTTS1 
gene, a mutation causing hearing loss or making the individual more susceptible to 
developing hearing loss following the administration of aminoglycosides. The screening 
of the mitochondrial genome also lead to the discovery of possible relationships among 
families by comparing their mitochondrial haplotypes.  
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Overall, a total of 10 significant variants were found in 18 probands, 7 of these 
variants require further discussion and research and 3 are known to be pathogenic and 
cause hearing loss. A detailed summary of the gene variants found in this study is shown 
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Sanger	  sequencing	  revealed	  a	  total	  of	  five	  variants	  
in	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  31	  and	  	  
.	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  1	  
and	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(c.421C>T,	  p.	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  ;	  c.545G>A,	  p.G182D;	  and	  








Figure 3.2. Samples of sequencing showing no mutations were found in the genes 
known to cause hearing loss in Newfoundland, A. WFS1 Exon 8, B. TMRPSS3 Exon 4, 




























Figure 3.3. An electropherogram showing an individual with a wild type Connexin 
26 gene (A) and an electropherogram showing a heterozygous deletion of a 






































Figure 3.4. An agarose Gel showing heterozygous Connexin 30 deletion in 
proband from family 2155  
For the corresponding family numbers for each DNA sample number see 
Appendix 5. 
Key: 
Well 1 – Ladder          Well 10 – FC08-213         Well 19 – JK08 - 229 
Well 2 - MT08-239     Well 11 – KS08-195         Well 20 – GH08-233 
Well 3 – MR08-325    Well 12- RH08-210          Well 21 – LP09-31 
Well 4 – EF08-238      Well 13-08MG1184         Well 22 – EW09-43 
Well 5 - MA08-234     Well 14 – JO08-216         Well 23 - Blank 
Well 6 – DB08-193     Well 15 – 03MG365B      Well 24 - Blank 
Well 7 – RP08-193      Well 16 – BM09-25         Well 25 - Blank 
Well 8 - CR09-48        Well 17 – AC08-223        Well 26 - Ladder 
Well 9 – DA08-201     Well 18 – JH08-220 
	  
	  














Figure 3.5. The partial pedigree for family 2155 showing autosomal recessive 
transmission of hearing loss in which the proband (arrow) that carries the connexin 26 
35delG mutation as well as the connexin 30 deletion. For the full pedigree see Appendix 
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Figure 3.7 An electropherogram showing heterozygous deletion of a guanine 
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Figure 3.9. An electropherogram showing the nucleotide change c.250A>AG 




























Figure 3.10.  A weblogo image pointing out the conservation of the amino acid at 



























Figure 3.11. A partial pedigree for family 2167 in which the proband (arrow) that 
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Figure 3.12. An electropherogram showing the homoplasmic change of guanine to 























Figure 3.13. The pedigree for family 2112 in which the proband (arrow) carries a 









































Figure 3.14. The pedigree for family 2144 in which the probands (arrow) carries 


























Figure 3.15. An electropherogram showing the homoplasmic change of 



























Figure 3.16. An electropherogram showing the homoplasmic change of adenosine 
























Figure 3.17. The pedigree for family 2072 in which the proband (arrow) and her 
mother have homoplasmic changes (C150T and T152C) in the control region of 
mitochondrial genome that caused the mispriming during MTRNR1 sequencing. 
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Daughter      Mother     Control    Ladder 
Figure 3.18. An agarose gel showing the apparent deletion in the proband 
and the proband’s mother from family 2072. 
	  
	  



















Figure 3.19. The wild type sequence of the human mitochondrial genome showing the 
sequence where the 3’ end of the forward primer was initially supposed to attach 
(pink) and the similar sequence 349 bps downstream from that point (light blue). 
Because it is important for primers to be specific, the SNPs in the proband’s 
mitochondrial genome at the binding site caused the primer to bind 349 bps away from 





























Figure 3.20. A partial pedigree for family 2010 in which the proband (black arrow) 
and 4 of her family members have homoplasmic changes (C150T and T152C) in the 
control region of mitochondrial genome that caused the mispriming during MTRNR1 
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Figure 3.21. Audiograms for the proband (A) and her mother (B) from family 
2072 and the audiogram for the proband (C) from family 2010. All showing high 
frequency hearing loss. 
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Figure 3.22. The pedigree for family 2078. The proband of this family was found to have 
































Figure 3.23. The pedigree for family 2075. The proband of this family was found to 
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Figure 3.24. A partial pedigree for family 2097. The proband of this family was found 
to have a heterozygous c.94C>T:p.R32W mutation in Cx31. For the full pedigree see 
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Figure 3.25. The pedigree for family 2156. The proband of this family was found to 
have a heterozygous c.94C>T:p.R32W mutation in connexin 31. 
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Figure 3.27 The pedigree for family 2078 showing the family members 
with the heterozygous c.94 C>T mutation. 
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Figure 3.31. The pedigree for family 2124. The proband of this family was found to 
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Figure 3.32. The pedigree for family 2065. The proband from this family has the 
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Figure 3.34. The pedigree for family 2177. The proband from this family has the 
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Figure 3.35. The pedigree for family 2092. The proband from this family has the 
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Table 1. Prediction of the Connexin 26 F83L Variant Effect. 
Program:         SIFT              Polyphen             SNPs3D                PMut 
F83L 
Variant:      Tolerated           Benign               Tolerated           Neutral 
 
Five bioinformatic programs were used to predict the effect of the F83L mutation.  
The overall evaluation predicts this mutation to be benign.  
 



























































































































































































	   	  








































































































































Category of Hearing Loss Number of probands with the Specified Type of Hearing 
Loss 
Low Frequency  5 
Mid Frequency 2 
High Frequency 29 












NM_024009 c.109G>A, p. V37M 
























Table 4. The number of probands in each category of hearing loss frequency 
	  























































































































The purpose of this study was to determine the genetic etiology of probands 
affected by nonsyndromic hereditary hearing loss. The probands in this study are all 
originally from the island of Newfoundland, a founder population. An island with a 
founder population is an ideal place for genetic studies. This study focused on families 
with a history of hearing loss. Previous studies on hearing loss in the Newfoundland 
population found causative mutations in WFS1¸ TMPRSS3, and PCDH15. These 
mutations, however, were not found in the families involved in this project. Mutations 
were identified in the mitochondrial gene, MTRNR1, as well as nuclear genes, Cx26, 
Cx30, Cx31, and TMC1.  
4.1 Screening Probands for Mutations previously found in the NL Population 
  
The initial step of this study was to screen all probands for mutations in genes 
previously found to cause hearing loss in the Newfoundland population. In 2001, A p. 
2146 G>A mutation that was causing a dominant form of inherited progressive deafness 
was identified in the WFS1 gene (Young et al.). Two recessive mutations in TMPRSS3 
were found to underlie hearing loss in a six-generation family from the south coast of 
Newfoundland (Ahmed et al., 2004), and Doucette et al. (2009) identified a novel 
mutation in PCDH15 causing profound hearing loss in another south coast family. All 
110 probands were screened for these mutations, however all individuals were negative. 




be expected that the mutations would show up while screening a group of individuals 
with hearing loss from the island. It is possible that the sample considered in this study 
was not large enough. In future studies, more hearing loss patients should be recruited to 
determine the accuracy of describing the NL mutations (in WFS1, TMRSS3, and 
PCDH15) as founder mutations.  
4.2 Proband from family 2155 with Hearing Loss Caused by Mutations in connexin 
26 & Connexin 30 
 
Mutations in genes that are located in the DFNB1 locus, connexin 26 (Cx26) and 
connexin 30 (Cx30), are the cause of 30-50% of this type of hearing loss (Bhalla et al., 
2009). I therefore decided to screen all probands for mutations in these genes once the 
NL mutations were ruled out.  
The proband from family 2155 was found to carry a heterozygous c.35delG 
mutation in exon 2 of Cx26 as well as a heterozygous 342 kb deletion in Cx30. These 
genes encode connexin proteins. If only one of the genes has a mutation (i.e. a 
heterozygous mutation), there is enough functional protein produced to allow the gap 
junctions to function properly, therefore there must be a homozygous mutation in either 
Cx26 or Cx30, or one mutation in each of the genes, to cause hearing loss (Smith et al., 
2014). In the case of the proband from family 2155 there is a heterozygous 35delG 
mutation in connexin 26 and a heterozygous 342 kb deletion in connexin 30 together 
causing hearing loss through digenic inheritance. The c.35delG mutation in connexin 26 
is a known mutation first found in hearing impaired Mediterranean patients in 1997 by 




result of a worldwide founder effect (Laer et al., 2001). The deletion of a guanine at 
position 35 in exon 2 of connexin 26 is a frameshift mutation that leads to premature 
chain termination causing the production of a truncated, dysfunctional connexin 26 
protein. The large deletion in connexin 30, given the name Δ(GJB6-D13S1830), truncates 
the connexin 30 protein, in addition, the deleted portion contains a cis regulatory element,  
that regulates the production of the connexin 26 protein (Rodriguez-Paris et al., 2011). 
With the deletion of this regulatory element in the connexin 30 gene, the expression of 
the connexin 26 protein is terminated, therefore no connexin 26 protein is produced (del 
Castillo et al., 2002). In European populations this deletion is the second most frequent 
mutation related to autosomal recessive hearing loss (Esteves et al., 2013). Thus, the 
presence of both mutations causes the hearing loss that affects the proband from family 
2155.  
Digenic inheritance of the 35delG mutation in connexin 26 and Δ(GJB6-
D13S1830) in connexin 30 has been shown to cause variable hearing loss. In one study 
published in 2004 (Bolz et al.) the severity of hearing loss due to this digenic inheritance 
was significantly different between the two families included in the study, with one 
family affected by profound hearing impairment and the other affected by 
moderate/severe hearing loss. The reason for the difference in phenotype in this case is 
that homozygous mutations in both Cx26 and Cx30 are found in affected members of the 
families. Therefore the severity of the phenotype depends on which mutations the 
individual carries. Within one family there can be different combinations of the 




could be caused by a modifier element that is upregulating connexin 26 or connexin 30.  
The hearing loss is generally more severe if the patient has a homozygous mutation in 
connexin 26 or connexin 30 (Bolz et al., 2004; Erbe et al., 2004; Marlin et al., 2005). 
However, a different study found probands with del(GJB6-D13S1830)/c.35delG 
presented with a more severe hearing impairment (Batissoco et al., 2009). Another study 
published in 2013, by Esteves et al., states that patterns of hearing loss caused by 
mutations in the connexin 26 gene have not been established, and there is no consistent 
model of the phenotype caused by malfunctioning or nonfunctioning connexin 26 
proteins. Therefore the phenotype caused by the digenic inheritance of the 35delG 
mutation and Δ(GJB6-D13S1830) in connexin 30 is still uncertain.  The severity of 
hearing loss caused by mutations in Cx26 and Cx30 is highly variable, so it is difficult to 
associate these mutations with a specific severity (Cama et al., 2009; Esteves et al., 
2013). 
The proband from family 2155 is a 25-year-old woman who was diagnosed with 
bilateral, profound, sensorineural hearing loss at the age of 18 months. It was recognized 
at the age of 9 months that the proband had no speech development, and it is assumed 
that she was hearing impaired since birth.  As mentioned, the hearing loss phenotype 
caused by Cx26 and Cx30 mutations is variable, and the hearing loss presented by this 
proband is of similar clinical presentation found in previous studies (Cama et al., 2009; 
Esteves et al., 2013). It is also a similar clinical presentation given for DFNB1 hearing 
loss, which is congenital, non-progressive, mild-to-profound sensorineural hearing 




/sites/GeneTests/ review?db=GeneTests on July 15, 2011). As both genes are found 
within the DFNB1 locus, the mutations found in this proband justify the hearing loss 
profile.	  
4.3 Proband from family 2197 found to have a heterozygous 35delG mutation in 
Cx26  
	  
A heterozygous 35delG mutation was found in exon 2 of Cx26 in the proband 
from family 2197 (Fig.3.6). This mutation alone is not the cause of hearing loss in this 
individual, as the 35delG mutation in Cx26 has never been reported to cause hearing loss 
in the heterozygous state (Kaskalan et al., 2014). I screened Cx30 in this individual, 
however no mutations were detected. This proband was also included in all further gene 
screening, which resulted in no additional mutation detection. This individual has a 
bilateral asymmetric hearing loss that was diagnosed at age 29 and is more profound in 
the right ear. There is no medical information available for this person’s family; therefore 
it is difficult to determine if the single deafness allele was inherited or has arisen de novo.  
 
4.4 A heterozygous F83L variant in Cx26 exon 2 in the proband from family 2091 
 
The proband from family 2091 was found to have a heterozygous F83L variant in 
Cx26, exon 2.  Using four bioinformatics programs to predict the pathogenicity of this 
variant, all predict this missense variant to be benign (Table 1). As well the Weblogo 
(Fig.3.10) shows that the phenylalanine at position 83 is not well conserved. The variant 




et al., 2012). I concluded that this variant is probably not responsible for causing hearing 
loss in the proband.  There was no audiogram available for this patient so it was difficult 
to choose candidate genes based on audioprofiling. Obtaining a more extensive medical 
background for the individual and the family would help for future studies. 
4.5 Variants in the Mitochondrial Genome 
	  
Mutations in two mitochondrial genes (MTRNR1 and MTTS1) have been 
identified to cause hearing loss. The mitochondrial genome is exceptionally polymorphic 
and varies greatly among individuals. Sometimes these variants are disease causing, such 
as the case with A1555G in MTRNR1, and at other times there are variants commonly 
found in the general population (Kazuno et al., 2006). I chose to screen for mutations in 
the mitochondrial genes following the screening for Cx26 and Cx30 mutations as 
mutations in the mitochondrial genome are one of the most common cause of 
nonsyndromic hearing loss (Guo, 2008). I screened MTRNR1 and MTTS1 in all unsolved 
probands. Seven polymorphisms were found and two probands were found to have the 
A1555G mutation in MTRNR1. 	  
4.6 Probands from families 2112 and 2144 Hearing Loss caused by a mutation in 
MTRNR1  
 
 The probands from families 2112 and 2144 were found to have a homoplasmic 
A1555G mutation in the MTRNR1 gene. MTRNR1 is a mitochondrial gene that codes for 
the 952 nucleotide long 12S ribosomal RNA (rRNA). The substitution of a guanine for an 




known to cause aminoglycoside induced hearing loss. Aminoglycosides are a group of 
antibiotics that rid the body of harmful bacteria by binding to their 16S rRNA in the 30S 
ribosomal subunit and inhibiting protein synthesis. The A1555G mutation causes the 12S 
rRNA to resemble the bacterial 30S rRNA, thus when an individual with the A1555G 
mutation is given aminoglycoside treatment, the aminoglycosides will inhibit protein 
synthesis within their mitochondria (Guan, 2011).  
The proband from family 2112 has been diagnosed with severe to profound 
bilateral hearing loss. She self-described being late deafened, having lost her hearing after 
an intravenous antibiotic treatment for pneumonia (which the individual reported as 
penicillin, not an aminoglycoside). The proband reported that her mother was affected 
with hearing loss after she was treated for tuberculosis in the 1950s. This medical 
information possibly links the hearing loss to the mitochondrial A1555G mutation in the 
proband, as well as the proband’s mother, obtaining DNA from the proband’s mother 
would help confirm this. In the 1950s, tuberculosis was treated using streptomycin, an 
aminoglycoside (Mitchison, 2005). Individuals who have the A1555G mutation often 
develop hearing loss following the administration of aminoglycosides (Guan, 2011). The 
proband of family 2112 has three siblings, all male; one affected by progressive bilateral 
hearing loss. However, DNA was not available for these individuals.  
The hearing loss in family 2112 is likely a case where both genetics and 
environment come into play. The A1555G mutation is not known to cause hearing loss 
on its own, but can predispose an individual to lose hearing when exposed to 




environmental factors can be the cause of a condition. It is common to attribute hearing 
loss to an environmental cause, such as a head injury, medication, infection, or noise 
pollution. However, the appearance of hearing loss after such occurrences could be 
purely coincidental, or predisposed by a genetic cause. Accepting that an environmental 
occurrence is the only reason for an individual’s hearing loss and failing to further 
investigate the reason a person develops the disorder can result in the omission of an 
underlying genetic cause.  
The proband from family 2144, with MTRNR1 A1555G, reports that her hearing 
loss began during childhood after an airplane flight and an ear infection and it has been 
getting progressively worse since then. She has had repeated ear infections as well as 
premature graying, a minor diagnostic criterion for syndromic deafness known as 
Waardenburg Syndrome (Nayak and Isaacson, 2003). As there is little information 
pertaining to this probands medical history and family history it is difficult to make 
connections between her hearing loss and genotype. Again, obtaining more information 
from the families should be looked into as further studies would help shed more light on 
this mutation and the environmental triggers of genetic hearing loss.  
4.7 A G951A variant in MTRNR1 found in two probands from families 2167 and 
2197 
A G951A variant in MTRNR1 was found in the proband from family 2167 
(Fig.3.11) and in the proband from family 2197, who also has a heterozygous 35delG 
mutation in connexin 26 as previously discussed (Fig.3.6). It cannot be concluded that 
this mitochondrial variant is the cause of the hearing loss expressed by these individuals. 




vestibulopathy (damage to the inner ear(s) causing dizziness, imbalance, and vision 
disturbances) and also in 155 healthy controls. None of the individuals sequenced had 
mutations in the mitochondrial genes that are known to cause hearing loss (A1555G or 
C1494T). They did find four mutations with putative pathogenic effects, T669C, 
C960del, C960ins, and T961G. They also found five frequent polymorphisms: G709A, 
G930A, T1189C, T1243C, G1438A and seven of what they called “rare homoplasmic 
changes”: T669C, T721C, G951A, C960del, C960ins, T961G, and G1007A, when they 
compared the 12S rRNA sequence to the Cambridge reference sequence (Elstner et al., 
2008). G951A was not found in 155 healthy patients; however they reported that no 
assumptions could be made about this variant and concluded that none of the variants 
they found had proven pathogenicity (Elstner et al., 2008). The report by Elstner et al. 
(2008) was the only evidence of G951A in the literature and it provided no information to 
the pathogenicity of G951A. Given the limited evidence, it can only be concluded that the 
G951A variant is of unknown pathogenicity. Further investigation of the genotype is 
required to determine the effect of the G951A variant.  
The proband from family 2167 (Fig.3.11) was diagnosed with unilateral mild to 
moderately severe sensorineural hearing loss in his left ear that presents in a “cookie bite” 
audiometric configuration (severe hearing loss in the mid frequencies with mild to no 
hearing loss in the higher and lower frequencies). He self reports that the hearing loss is 
progressing and that he is also affected by premature graying (before the age of 30) as 
well as kidney problems. He also reports that he had multiple left sided ear infections 




examination at age four. There are three distant relatives that have been diagnosed as 
deaf. Acquiring their DNA may not help to determine the pathogenicity of the G951A 
mutation because all relatives diagnosed as deaf are on the paternal side of the family, 
however, if the proband’s mother and father are descendants of the same maternal 
ancestor it is possible that both the mother and father have this mutation. It would be 
beneficial to obtain more information on the maternal side of the family to help solve the 
questions of pathogenicity that surround the G951A variant.  
The proband from family 2197 has a bilateral asymmetric hearing loss that was 
diagnosed at age 29 and is more profound in the right ear. There was no available 
audiogram; therefore it was difficult to choose candidate genes based on audioprofiling. 
The proband had an affected father as well as two affected uncles. The paternal 
grandmother was also affected, suggesting that hearing loss was segregating as a 
dominant trait on the paternal side  This proband also has a heterozygous 35delG 
mutation in connexin 26. It is possible that an interaction between connexin 26 and 
mitochondrial mutations may be having an effect in this individual. However, because no 
conclusion can be drawn as to whether or not the G951A mutation is pathogenic, then it 
is difficult to say it is affecting the wild type connexin 26 gene. A literature search 
revealed no previous studies that discussed the G951A mutation in connection with a 
connexin 26 mutation.  Future studies should look closely at the interaction between 




4.8 MTRNR1 common variants 
There are many common variants in mitochondrial DNA that are not associated 
with disease, including six such variants in MTRNR1 (Retrieved from http://www.mito 
map.org/MITOMAP on May 31, 2011): G709A, A750G, A751G, G930A, T1189C, and 
G1438A. Five of these variants are previously reported as found at significant 
frequencies across several ethnic groups. Because they are at a frequency greater than 1% 
in the general population, these mitochondrial variants are considered common variants 
(Lu et al., 2010; Rydzanicz et al., 2010; Elstner et al., 2008; Li et al., 2004). In 2004 Li et 
al., in their study of 164 Caucasian subjects under 19 years of age who were diagnosed 
with nonsyndromic sensorineural deafness, reported that A751G was a novel 
polymorphism in the Caucasian population. In 2009, a Polish group, Rydzanicz et al., 
found this sequence variant and submitted it to MITOMAP (reference #20071219002) as 
it had not been reported on MITOMAP at that time. They called A751G a nucleotide 
change, but made no other comment about its pathogenicity. No variants, pathogenic or 
non-pathogenic, were found in MTTS1. 
The associations made between mitochondrial variants and disease are dependent 
on population genetics and because of the variability of the mitochondrial genome it is 
often difficult to make conclusions about the pathogenicity of a polymorphism (Kazuno 
et al., 2006). The variants found in this study have been published multiple times; 





4.9 Specificity of Mitochondrial Primer Binding Sites  
 
The proband from family 2072 appeared to have a mitochondrial deletion, 
however, following several attempts using different primer sequences a high quality 
sequence was finally obtained and sequence analysis showed that two SNPs (C150T, and 
T152C) were present in the mitochondrial DNA of the proband, therefore the hypothesis 
that the primer is hybridizing at a point 349 bp away from the intended primer 
hybridization site is most likely correct. To further support this hypothesis, specificity at 
the 3’ end of a primer to the DNA sequence is extremely important as primers that have 
poor specificity in this region usually produce undesirable amplicons (Dieffenbach, T, & 
G, 1993). In order to have a successful PCR it is important to have the correct placement 
of the 3’ end of a primer so that perfect base-pairing between the 3’ end of the primer and 
the template DNA is necessary and minimal mismatch should be present (Dieffenbach et 
al., 1993). Therefore, the presence of these SNPs where the 3’ end of the primer should 
hybridize decreases the specificity of the primer and causes the primer to hybridize at a 
position 349 base pairs away that matches the last six base pairs of the 3’ end of the 
primer. 
4.10 Matching Mitochondrial Haplotypes 
	  
Following the discovery that the probands of family 2010 and 2072 has the same 
SNPs in their mitochondrial DNA, I thought it would be interesting to see if their 
mitochondrial haplotype was identical. No other families had the same combination of 




likely, as they appear to have the same haplotype and they come from the same area of 
the island of Newfoundland. Upon the discovery of the similarity of the SNPs found in 
these two families, the audiograms were analyzed and it was noticed that the audiograms 
that were available for the family members of 2010 and 2072 showed very similar 
hearing loss patterns (Fig.3.21). The original SNPs found in these families (C150T and 
T152C) could play a role in the hearing loss that the affected members have, or they 
might just indicate that these families are related through the maternal line, and have the 
same type of hearing loss caused by possible shared mutations. The audiograms and 
family history of all other probands showing similar mitochondrial haplotypes should be 
analyzed to see if they have similar hearing loss patterns.  
4.11 Connexin 31 Variants 
Mutations in connexin 31 have been shown to cause both dominant and recessive 
hearing loss (Liu et al., 2000). Two mutations have been reported to cause dominant 
hearing loss, R180X and E183K, and two mutations have been found to cause recessive 
hearing loss, 141del_Ile, and I141V (Retrieved from http://hereditaryhearingloss.org on 
May 12, 2014). Few publications regarding this connection exist in the literature 
(Retrieved from davinci.crg.es/deafness/ on May 12, 2014).  The recessive mutations 
were found in a study of 25 Chinese families with apparent recessive hearing loss.  The 
study, conducted by Liu et al. (2000), found a sibling pair, with severe hearing loss at all 
frequencies, and a single proband with moderate hearing loss at all frequencies, to be 
compound heterozygotes for the 141delIle and I141V mutations, neither of the parents 




had high frequency hearing loss, which does not fit the phenotype for recessive connexin 
31 hearing loss found in the study by Liu et al. (2000). However, the gene was suggested 
as a candidate following the audioprofile investigation, and so screening went ahead.  
Connexin 31 was screened in 29 probands with high frequency hearing loss and 
two variants were discovered in 7 probands. The variant c.109G>A, p.V37M was found 
in 1 proband;  and c.94C>T, p.R32W was found in 6 probands. 
The variant c.109G>A, p.V37M was found in family 2083 (Fig.3.26). The 
proband from this family has postlingual hearing loss, which was reported to have 
occurred between the ages of 3 and 25. Xia et al. (1998) report that autosomal dominant 
deafness caused by a c.538C>T in patients who lost their hearing in late adulthood; this 
onset is dissimilar to the onset in this proband. In order to reach a conclusion about the 
pathogenicity of this variant, a more detailed medical history of the proband is required 
as well as DNA from the probands family members.  
The mutation c.94C>T, p.R32W was found in six families. The families with this 
Cx31 mutation are: family 2155(Fig.3.5), family 2167 (Fig. 3.11), family 2078 (Fig. 
3.22), family 2075 (Fig. 3.23), family 2097 (Fig. 3.24), and family 2156 (Fig 3.25). The 
proband from family 2097 has postlingual hearing loss diagnosed between the ages of 3 
and 25; this proband also has a heterozygous connexin 30 deletion Δ (GJB6-D13S1830). 
While it has not yet been determined that these two mutations cause hearing loss when 
inherited together, it is worth looking into for future studies. The proband from family 




inheritance of the 35delG mutation in connexin 26 and Δ(GJB6-D13S1830) in connexin 
30. This proband is also homozygous for R32W in connexin 31. These mutations have 
not been found inherited together, and there is no published evidence of these two genes 
interacting, but it is possible that having mutation in three of these connexin genes could 
increase the severity of the hearing loss and is worth looking into in future studies. The 
proband from family 2075 has a history of postlingual hearing loss diagnosed between 
the ages of 3 and 35. The proband from family 2156 also has adult onset hearing loss, 
diagnosed between 26-50 years old. The proband from family 2078 (Fig.3.22) has 
postlingual hearing loss. The proband from family 2167 has been previously mentioned 
as he has a variant in the mitochondrial DNA, he was diagnosed between the ages of 3 
and 25, he hears well at low and high frequencies but not at middle frequencies. This is 
called a “cookie bite” curve on an audiogram because the curve is high on both ends but 
low in the middle and appears as if there is a bite taken out of it. All of these probands 
present with different types of hearing loss, and given the variability of hearing loss 
caused by mutations in connexin 31 (OMIM) you cannot rule out either of them based on 
phenotype. However, the pathogenicity of R32W has been questioned in the literature. In 
one study, R32W was found in hearing loss patients, but was also found in 18 percent of 
the control population (Lopez-Bigas et al., 2000). Rouan et al. (2003) used HeLa cells to 
test Cx31 function when the R32W variant was present, and found no deviations in 
expression level, concluding that it is an inconsequential polymorphism. 
It is interesting that these variants appear to segregate with hearing loss in these 




pathogenicity (Fig.3.27, 3.28, 3.29, 3.30). Therefore in future studies segregation analysis 
should be performed. In addition to segregation analysis it would be extremely beneficial 
to obtain a more detailed family and medical history for each of these probands, given 
that the family would be willing to divulge that information.  
 4.12 TMC1 Variants 
Mutations in the TMC1 gene are known to cause nonsyndromic autosomal 
dominant and autosomal recessive hearing loss (Hereditary Hearing Loss Homepage, 
OMIM, www.omim.org).  Almost all reported cases of TMC1 hearing loss report pre-
lingual severe to profound hearing loss (OMIM; Gao et al., 2013). TMC1 is a second 
gene that was suggested as a candidate gene for hearing loss probands following the 
audioprofiling investigation. Three mutations were found in TMC1: c.545G>A:p.G182D 
in the proband from family 2124, c.1763+3A>G in the proband from family 2065 (Fig. 
3.32), and R141W in the proband from families 2010 (Fig. 3.20), 2146 (Fig. 3.33), 2177 
(Fig.3.34), and 2092 (Fig.3.35). All of these probands are affected by post lingual hearing 
loss. There is no additional information on the proband from family 2124 (Fig. 3.31).  
The proband from family 2065, with the intronic mutation, c.1763+3A>G., was 
born in 1996 and has bilateral symmetrical sensorineural mild to moderate hearing loss in 
the low frequencies (250-750 Hz), and severe hearing loss in high frequencies (1000-
8000Hz) that progressed rapidly in the first decade of his life. Mutations in TMC1 
causing nonsyndromic hearing loss have been found more commonly in Pakistani 




Caucasian family (Kitajiri et al., 2007). The affected members from this family had 
postlingual, progressive sensorineural hearing loss, which presented in the second decade 
of life, starting in the high frequencies. The mutation found in this family was a missense 
substitution c.G1714C, p.D572H, and falls within a large cytoplasmic loop region of the 
TMC1 protein (Kitajiri et al., 2007; Labay et al., 2010 ). While this mutation was not 
found in the proband from family 2065, the region of TMC1 that is mutated in the 
proband lies within an intron of close proximity. Analysis of this mutation and of the 
proband’s family is required to determine the pathogenicity of the c.1763+3A>G variant. 
The proband from family 2010, with the R141W mutation, was born in 1965 and 
has normal bilateral hearing at 250-500 Hz (low frequency), with a precipitous slope over 
500 Hz where the hearing loss (bilateral and sensorineural) becomes moderately severe to 
profound in high frequencies. The proband has two male relatives, who report having 
hearing loss by age five, one of which had normal hearing at birth and in the other, the 
age of onset is unknown. This proband also has more severe hearing loss in the higher 
frequencies which is also the case with the TMC1 hearing loss in the North American 
family reported by Kitajari et al. (2007). Acquiring DNA from the proband’s family 
members is essential in determining the pathogenicity of this variant. 
The proband from family 2092 was born in 1935. She has flat line hearing loss 
(i.e. absolutely no sense of hearing) in her right ear. In her left ear she has mild sloping to 
moderately severe sensorineural hearing loss in the mid to high frequencies. Audiograms 
of other relatives show symmetrical bilateral loss, the same as this proband is 




frequencies, which appears to be the case in the only Caucasian family identified to have 
hearing loss caused by a mutated TMC1 gene (Kitajiri et al., 2007). There is no 
information as to the rate of progression of hearing loss for this individual. To determine 
the effect of the mutation, DNA should be acquired from the available family members.  
 The proband from family 2146, born in 1958, is affected by right severe to 
profound reverse slope sensorineural hearing loss. In his left ear he experiences steep 
high frequency sensorineural hearing loss above 2000 Hz. He reports normal hearing 
bilaterally at age 8-10 years and an onset of Meniere’s disease (a disease causing sporadic 
episodes of vertigo, sensorineural hearing loss, tinnitus and ear pressure ;OMIM, 
www.omim.org) symptoms in his right ear at age 37. He displays hearing loss, vertigo 
attacks, tinnitus and ear fullness, all symptoms of classic Meniere’s disease with classic 
progression in the right ear over 15 years with increasing hearing loss with every attack, 
and partial recovery of hearing to the previous level between attacks. The high frequency 
hearing loss appears to be common among all individuals found to have mutations in 
TMC1. Because this type of hearing loss was displayed in the Caucausian family with 
TMC1 hearing loss (Kitajiri et al., 2007) this could be an indication that it may be causing 
hearing loss in these individuals. There has been no evidence of TMC1 mutations 
associated with Meniere’s disease.  
 Lastly, the proband from family 2177 was born in 1961 and has right borderline 
mild low frequency sloping to moderately severe high frequency sensorineural hearing 
loss, which is reported to have started during childhood. The left ear is affected by left 




a tentative diagnosis of Meniere’s disease, but it is not a classic presentation. The 
proband’s aunt and brother reported having a diagnosis of Meniere’s disease with 
asymmetric hearing loss. This individual also displays more severe hearing loss in the 
high frequencies, which was seen in all other probands with TMC1 mutations. Both 
bilateral hearing loss and asymmetrical hearing loss has been displayed in the probands, 
and the TMC1 mutations causing hearing loss do not seem to specifically cause one or the 
other (Kitajiri et al., 2007). This proband has also been diagnosed with Meniere’s 
disease, which is interesting and worth looking into, if it were found to be the result of 
the TMC1 mutation, it would be the first known case.  
 Like the probands with connexin 31 mutations, it will be necessary to perform 
segregation analysis to verify the pathogenicity of the variants found. Also, retrieving a 
more detailed family history may also present clues as to what type of hearing loss affects 
these probands. It would be valuable to have an extensive family history and medical 




Overall the study resolved the etiology for four hearing loss probands out of 110 
that were screened. One proband has hearing loss caused by a homozygous 35delG 
mutation in connexin 26, another proband has hearing loss caused by the digenic 
inheritance of the 35delG mutation in connexin 26 and del13S1830 in connexin 30. Two 




Other probands (n=7) have variations in connexin 31 and 6 others have variations in 
TMC1, yet these cannot be considered resolved because segregation analysis has not yet 
been performed to confirm the pathogenicity of the variants.  
In addition, this study found that none of the probands recruited for this project 
had mutations previously found to cause hearing loss in the Newfoundland population 
(TMPRSS3, PCDH15, and WFS1). Inviting questions as to whether or not these are 
actually founder mutations.  Also of interest are the similarities between mitochondrial 
haplotypes of several of the probands, especially those from family 2072 and 2010. The 
affected members of this family appear to have the same type of hearing loss, however an 
underlying genetic cause could not be identified. This study has brought forward 
mutations in several genes (Cx31, TMC1, MTRNR1) that were not previously found in the 
Newfoundland population. These findings create many opportunities to further explore 
the genetic etiology of hearing loss in this province. 
Determining the underlying cause of hearing loss in Newfoundland and Labrador 
will improve the province’s screening strategies so that this disorder can be identified as 
early as possible. Recognizing hearing loss early in life can positively impact a child and 
the ability to learn communication skills and participate in a school environment. 
Children who are identified as hearing impaired can be taught to communicate in a 
specialized manner or can also benefit from certain types of hearing devices, such as 
hearing aids or cochlear implants. In addition to this, knowing the cause of deafness can 
offer relief to families who can then receive support from genetic counselors and 




5. Future Directions 
 
This study opens up many possibilities for future projects. First of all it is 
necessary to perform segregation analysis on the variants of connexin 31 found in 7 of 
the probands and the variants of TMC1 found in 6 of the probands, and to perform exome 
sequencing (sequencing only the coding regions) on the unsolved probands with the 
intent to find known and novel mutations. Secondly, it would be beneficially to recruit 
more family members and collect familial DNA for those probands that were lacking 
family medical history or for which there was no family DNA available (family 2197). 
Having the information and resources to further studies into the cause of their hearing 
loss may aid in finding a cause. A study could also be built around the mitochondrial 
haplotypes that were presented in this project. These haplotypes can be used to identify 
the relationships and origins of families. Linking haplotypes to phenotypes could 
potentially solve several families. More specifically it would be interesting to map the 
lineage of families 2072 and 2010 since this study discovered several similarities among 
the members of these families affected by hearing loss. Lastly because this study dealt 
with a small population of deaf probands a recruitment project could bring in more 
families affected by this disorder. Screening the families would give a more in depth look 
at mutations previously identified as founder mutations within the Newfoundland 
population. 
While this study has significantly added to the research on hearing loss genetics it 
has also opened the door for many more projects to be explored. With the quick 




deafness, hopefully the studies can be carried out and conclusions can be drawn from the 
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Appendix 3: Standard DNA Extraction Protocol 
Purpose: To provide a method for the extraction, precipitation, and re-suspension of 
DNA from (EDTA) whole blood. 
Responsibilities: Lab personnel who have been trained in this procedure. 
Definitions: 
− hr. = hour 
− ppt = precipitate 
− WBC = white blood cell 
 
Equipment and Supplies:   
Equipment: 
− centrifuge 
− Biological safety cabinet 
− 37º or 55 ºC water bath or heat block 
− Pipette aid 
  
Supplies: 
− 50 ml &15ml centrifuge tubes 
− 1 & 10ml pipettes 
− 2 ml micrewtube with o-ring seal screw cap 
− “hooked” Pasteur pipettes 
− 500ml plastic beaker  
 
Reagents: 
− RBC lysis solution (NH4CL/Tris) 
− 0.85% NaCl 
− Nuclei lysis buffer (10mM Tris-HCl, 400mM NaCl, 2.0 mM EDTA, pH 8.0).   
− 10%SDS 
− Protease solution (3mg/ml protease, 1% SDS, 2mM EDTA)  
− Saturated NaCl 
− Absolute ethanol 
− TE buffer  




− TE buffer (10mM Tris, 1mM EDTA, pH 8.0) 
− Bleach (for disinfection). 
 
Procedure:  
Note: place a 1.0 litre plastic beaker containing ~100ml of bleach in the safety 
cabinet for waste discard/disinfection. Decant all supernatants etc. into this 
container. 
1. Pre-warm RBC lysis solution to 37ºC. 
2. In a 50ml centrifuge tube mix 5 vols. of RBC lysis solution with 1 vol. of whole 
blood (to avoid aerosols add the lysis solution first then the blood).  Mix by inverting 
and then incubate at 37ºC for 5min to 1 hr. 
3. Centrifuge at 1000 x g (2500 rpm) for 5min. 
4. Decant the supernatant and add 10 ml of 0.85% NaCl.  Vortex (vigorously) to re-
suspend the WBC pellet then centrifuge (as previous). 
5. Decant the supernatant and add 3ml of nuclei lysis buffer  
6. Vortex (vigorously) to re-suspend the WBC pellet then and add 0.2 ml of 10% SDS 
and 0.5ml of Protease solution. 
7. Incubate at 55ºC for 2 hr. or 37ºC for 12 to 60 hr. 
8. Add 1.0ml of saturated NaCl, shake/vortex vigorously for ~15sec. then centrifuge at 
1000 x g (~2500 rpm) for 15min’s. 
9. Carefully (so as not to disturb the pellet) decant the supernatant into a clean 15ml 
centrifuge tube containing 2 volumes of absolute ethanol and gently mix by inversion 
until a DNA ppt. is visible. If the ppt. is not visible check the underside of the tube 
cap – sometimes the DNA lodges there!  
10. “Hook” the DNA ppt. with a (“hooked”) Pasteur pipette, decant the waste from the 
tube, and then place the inverted pipette back into the tube. 
11. Wash the DNA with a stream of (~ 2-5ml) of 70% ethanol (the ethanol will flow 
down the pipette and into the tube). 
12. Break off the hooked end (containing the DNA) of the pipette into a 2 ml micrewtube 
with o-ring seal screw cap. Add 1.0ml of TE buffer and store at 4ºC. 
13. DNA can be quantitated (UV 260/280nm) after 24 hr storage at 4ºC or >2hr. at 37ºC. 
 
Potential Problems and Corrective Action: 
Potential Problem: DNA remains as a viscous “glob” in tube. 
Corrective Action: Incubate at 56 ºC for 1 hr. Or overnight at 37 ºC. 
Potential Problem: DNA remains as a viscous “glob” in tube even after incubation at 56                                                                                                                                                                                                                                                                                                                                                   
ºC for 1 hr. Or overnight at 37 ºC. 
Corrective Action: Add T.E. in 250µl increments; followed by incubation at 56 ºC for 







































































































































































































































Appendix 5: DNA sample numbers and their corresponding Family numbers for all 
probands screened along with what mutations were found (both previous and in this 
study) 
























Mutations in Connexin 26 and Connexin 30 cont’d 
 




Mutations in the Mitochondrial genome 

























Mutation in Connexin 31 and TMCI cont’d 
 
